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  Amifostine has been shown in randomized trials to protect the parotid gland, lung and 
esophagus from radiation. It is a thiophosphate prodrug that is dephosphorylated to the 
active free thiol metabolite, WR-1065, by plasma membrane-bound alkaline phosphatase. 
Selectivity of amifostine may be due to differences between the microenvironment of 
normal tissues and tumor (e.g., pH and enzymatic activity) and different uptake 
processes.      
  We proposed to optimize the use of amifostine as a radiation protector of normal liver, 
which will permit the safe delivery of higher doses of radiation for patients with both 
focal and diffuse disease. We carried out nonclinical studies to optimize amifostine 
selectivity (i.e., the concentration of WR-1065 in liver to tumor) in a rat xenograft model 
with different dosing routes of drug (systemic vs regional and IV vs SC). The 
pharmacokinetics of amifostine and WR-1065 were evaluated in a phase I trial of dose-
escalating radiation therapy with systemic amifostine for liver cancer patients. Following 
intravenous dosing of amifostine, the concentrations of WR-1065 in liver and blood were 
highest at the earliest sampling time and higher doses, while tumor levels were relatively 
constant with respect to time. Based on our response surface regression model, no 
significant difference was observed between systemic and regional administrations of 
amifostine. After subcutaneous dosing of amifostine, optimal selectivity was sustained 
for a period of 5-20 min. While the liver and tumor concentrations of WR-1065 were 





time. These findings recommend that the highest intravenous dose of amifostine tolerated 
be administered, and that radiotherapy begin shortly after dosing for liver cancer patients. 
A subcutaneous dose, which is an easier administration route, may be a reasonable 
substitute when dosed 5-20 min before radiotherapy. Clinical pharmacokinetic results 
indicated that amifostine has a short half-life, a small volume of distribution and a large 
clearance. WR-1065 has a much longer half-life, and larger volume of distribution and 
clearance as compared to amifostine. In conclusion, amifostine was converted to WR-
1065 rapidly and confined to extracellular fluid in the body. WR-1065 was extensively 












  The treatment of cancer with radiation therapy and/or chemotherapy has improved in 
recent years, but precisely targeting malignant tissue has remained a major challenge. 
While dose escalation may theoretically improve efficacy, toxic effects on nonmalignant 
tissues and organs continue to be dose limiting. To increase the therapeutic selectivity of 
chemotherapy and radiation therapy, researchers have tried either to heighten the 
sensitivity of tumor cells to treatment by three-dimensional radiation, regional drug 
delivery of chemotherapy and radio- and chemosensitizers, or to protect normal cells with 
the use of protective agents.[1] The use of protective agents is particularly interesting 
because of their potential to protect healthy tissue without compromising tumor cell 
destruction.[2] At present, the Food and Drug Administration (FDA) has approved 
dexrazoxane, mesna and amifostine, three cytoprotecting agents, for reducing the 
cytotoxicities associated with chemotherapy and/or radiotherapy of cancer treatment.[3] 
  Currently, the most potent and broad-spectrum selective chemo- and radioprotective 
agent known is amifostine.[4,5] Yet, by 2002 its only approved indications are for reducing 
the renal toxicity associated with cisplatin in patients with advanced ovarian cancer and 
non-small cell cancer of the lungs, and for reducing xerostomia associated with head and 







  Amifostine protects almost all normal tissues from the cytotoxic effects of radiation and 
some chemotherapeutic agents.[7,8] Amifostine is a thiophosphate prodrug that is 
dephosphorylated to the free thiol active metabolite, WR-1065, by the plasma membrane 
bound enzyme alkaline phosphatase.[9] A number of studies have attempted to 
characterize the mechanism of differential protection when amifostine is administered 
systemically. Amifostine may be actively absorbed by normal tissue cells and only 
passively absorbed by tumor cells.[10] The selective uptake of WR-1065 may also be due 
to differences in the tissue microenvironment resulting in the slow entry of the free thiol 
into tumor masses. Tumors are often relatively hypovascular and have low interstitial pH, 
resulting in low rates of prodrug activation by alkaline phosphatase. In addition, there is a 
plentiful distribution of alkaline phosphatase in capillaries and arterioles of normal 
tissues compared with tumors. Thus, in tumors it is thought that both reduced metabolism 
of amifostine to the active protector WR-1065 and the low uptake of WR-1065 by the 
tumor result in a concentration of the free thiol that is much lower than that found in 
normal organs.[11,12] As a result, healthy tissue is protected from radiotherapy and 
chemotherapy while tumors with lower levels of the active metabolite are less protected. 
Transient hypotension, however, is the major dose-limiting adverse effect of amifostine. 
It is associated with direct relaxation of vascular smooth muscle mediated by free WR-
1065.[13] The main metabolic pathway of WR-1065 elimination involves the formation of 
symmetrical and nonsymmetrical disulfides that might serve as a depot for the active 
metabolite, free WR-1065.[14] 
  Compared with intravenous administration, regional chemotherapy may deliver high 







drug. Amifostine is a good candidate for regional drug delivery to the liver because it has 
a large clearance from the body and is eliminated more extensively by the liver than by 
the gastrointestinal tract, lungs, or kidneys.[15-18] Approximately 90% of the drug is 
extracted by the liver (i.e., converted to WR-1065), suggesting that the liver may 
preferentially take up the active free thiol, WR-1065.[19] We hypothesize that organs with 
high amifostine clearance and extraction ratio would have a high activation rate of 
amifostine to WR-1065 and, therefore, would be protected by amifostine. Clinically, a 
simpler but equally effective mode of administration would make amifostine more 
convenient for both the patient and the practitioner. Subcutaneous administration of 
amifostine could potentially reduce the side effects of the drug and be significantly more 
convenient for both patients and radiation oncologists. To be clinically useful, the SC 
route would have to be as effective as IV administration. 
  Radiation therapy has played a minor role in the conventional management of patients 
with intrahepatic malignancies because the dose of radiation that can be delivered is 
limited by normal tissue toxicity referred to as radiation-induced liver disease (RILD). 
For patients with focal intrahepatic cancers, three dimensional treatment planning has 
permitted the delivery of high doses of radiation, leading to improved local control and, 
possibly, survival. However, many patients have disease that is too diffuse to be treated 
with focal techniques. Amifostine has been shown in randomized trials to protect the 
kidney from cisplatin nephrotoxicity and the parotid gland from radiation due to the 
greater conversion of the drug to the active metabolite WR-1065 in the normal tissue than 
in the tumor. Protection appears to result from scavenging oxygen-derived free radicals 







requires that the active metabolite be present at the time of radiation. WR-1065 may also 
affect the catalytic inactivation of topoisomerase II, which slows cell cycling, thus 
providing more time for DNA repair.[20] In order to optimize the use of amifostine as a 
radiation protector of normal liver, which will permit the safe delivery of higher doses of 
radiation for patients with both focal and diffuse disease, the following specific aims are 
proposed in this research: 
1. Phase I trial of dose escalating radiation therapy with systemic amifostine for 
patients with diffuse intrahepatic cancer. 
We hypothesize that systemic amifostine will permit meaningful selective protection of 
the normal liver, permitting radiation dose escalation. 
2. Preclinical studies to optimize selectivity and estimate the appropriate dose of 
regional amifostine. 
We hypothesize that regional amifostine will be superior to systemic amifostine in 
producing a higher liver to tumor ratio of WR-1065, causing greater selective 
protection of normal liver compared to tumor. 
3. Preclinical studies to optimize selectivity and estimate the appropriate dose of 
subcutaneous amifostine. 
We hypothesize that subcutaneous administration of amifostine will permit equal 













1. Phillips TL. Sensitizers and protectors in clinical oncology. Semin Oncol, 8:65-81, 
1981. 
 
2. Links M and Lewis C. Chemoprotectants: a review of their clinical pharmacology and 
therapeutic efficacy. Drugs, 57: 293-308, 1999. 
 
3. Hensley M, Schuchter LM, Lindley C, Meropol NJ, Cohen GI. American Society of 
Clinical Oncology: Clinical Practice Guidelines for the use of chemotherapy and 
radiotherapy protectants. J Clin Oncol, 17: 3333-3355, 1999. 
 
4. Tannehill SP and Mehta MP. Amifostine and radiation therapy: past, present, and 
future. Semin Oncol, 23: 69-77, 1996. 
 
5. Yuhas JM, Spellman JM and Culo F. The role of WR-2721 in radiotherapy and/or 
chemotherapy. Cancer Clin Trials, 3: 211-216, 1980. 
 
6. PDR (2000) Ethyol, in PHYSICIANS’ DESK REFERENCE 54 edition, Medical 
economics Company, Montvale, NJ. 
 
7. Milas, L., Hunter, N., Reid, B.O., and Thames, J., H.D. Protective effects of S-2-(3-
aminopropylamino) ethylphosphorothioic acid against radiation damage of normal 
tissues and a fibrosarcoma in mice. Cancer Res, 42: 18888-1897, 1982. 
 
8. Rasey, J.S., Nelson, N.J., Mahler,P., Anderson, K., Krohn, K.A., and Menard, T. 
Radioprotection of normal tissues against gamma rays and cyclotron neutrons with 
WR-2721-LD50 studies and 35S-WR-2721 biodistribution. Radiat Res, 97: 598-607, 
1984. 
 
9. Shaw, L. M., Bonner, H.S., and Brown, D.Q. Metabolic pathways of WR-2721 
(ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos, 22: 895-902, 1994. 
 
10. Yuhas, J.M. Active versus passive absorption kinetics as the basis for selective 
protection of normal tissues by S-2-(3-aminopropylamino) ethylphosphorothioic acid. 
Cancer Res, 40: 1519-1524, 1980. 
 
11. Calabro-Jones, P.M., Aguilera, J.A., Ward, J. F., Smoluk, G.D., and Fahey, R.C. 
Uptake of WR-2721 derivatives by cell in culture – Identification of the transported 
form of the drug. Cancer Res, 48: 3634-3640, 1988.  
 
12. Rasy, J. S., Grunbaum, A., Krohn, K.A., Menard, T. W., and Spence, A. M. 
Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl 








13. Ryan SV, Carrithers SL, Parkinson SJ, Skurk C, Nuss C, Pooler PM, Owen CS, Lefer 
AM.  Hypotensive mechanisms of amifostine. J Clin Pharm, 36: 365-373, 1996. 
 
14. Shaw LM, Bonner HS and Lieberman L. Pharmacokinetic profile of Amifostine. 
Semin Oncol, 23: 18-22, 1996. 
 
15. Symon, Z., Levi, M., Ensminger, W.D., Smith, D.E., and Lawrence, T.S. Selective 
radioprotection of hepatocytes by systemic and portal vein infusion of amifostine in a 
rat liver tumor model. Int J Radiat Oncol Biol Phys, 50: 473-478, 2001. 
 
16. Shaw, L.M., Bonner, H.S., Turrisi, A., Norfleet, A. L., and Kligerman, M. 
Measurement of S-2-(3-aminopropylamino) ethanethiol (WR-1065) in blood and 
tissue. J Liq Chromatogr, 9: 845-859, 1986. 
 
17. Burns, J. A., Butler, J. C., Moran, J., and Whitesides, G. M. Selective reduction of 
disulfides by tris(2-carboxyethyl) phosphine. J Org Chem, 56: 2648-2650, 1991. 
 
18. Shaw, L.M., Bonner, H.S., Turrisi, A., Norfleet, A. L., and Glover, D.J. A liquid 
chromatographic electrochemical assay for S-2-(3-aminopropylamino) 
ethylphosphorothioate (WR-2721) in human plasma. J Liq Chromatogr, 7: 2447-
2465, 1984.  
 
19. Levi, M., Knol, J.A., Ensminger, W.D., Deremer, S.J., Dou, C., Lunte, S.M., Bonner, 
H.S., Shaw, L.M., and Smith, D.E. Regional pharmacokinetics of amifostine in 
anesthetized dogs: role of the liver, gastrointestinal tract, lungs and kidneys. Drug 
Metab Dispos, 30: 1425-1430, 2002. 
 
20. Snder, R.D. and Grdina, D.J. Further evidence that the radioprotective aminothiol, 














BACKGROUND AND LITERATURE REVIEW 
 
2.1 Problems and solutions of intrahepatic cancer treatment 
  Approximately 20,000 patients die in the United States from uncontrolled intrahepatic 
cancer every year, resulting about equally from colorectal cancer metastatic to the liver 
and from primary hepatobiliary cancer.[1,2] In addition to that, thousands of patients suffer 
from liver metastases in the context of other systemic cancers (such as breast and lung 
cancer). However, radiation therapy has played a minor role in the conventional 
management of these patients. This is because the liver is relatively radiosensitive, with 
an estimated whole-liver tolerance dose of about 30-33 Gy at 1.5-2 Gy per fraction, and 
that such doses can (at best) produce only short-term palliation of macroscopic solid 
tumors. Treatment of the liver with more than this dose can result in radiation-induced 
liver disease known as RILD (traditionally, but inappropriately, called “radiation 
hepatitis”). Consequently, during much of the last 30 years, only low doses of radiation 
have been delivered to patients with intrahepatic cancers, producing few responses and 
little symptomatic liver toxicity. However, there has been a renewed interest in hepatic 
irradiation-induced hepatic toxicity because of two advances in the therapy of cancer 
patients. The first is the development of three-dimensional treatment planning.[3] The 







to focal well-defined volumes while sparing most of the normal liver.[4-7] Although this 
approach, by permitting the safe delivery of doses in excess of 70 Gy to some liver 
tumors, appears to improve the outcome of patients with intrahepatic cancer, a number of 
patients have developed clinical radiation liver injury. The second advance is the 
introduction of bone marrow transplantation, in which hepatic toxicity, in the form of 
veno-occlusive disease (VOD), is produced by the combined use of chemotherapy and 
total body irradiation as part of the preparative regime. 
  Needless to say, these toxicities can have a significant impact on the quality of life of 
the patient. Pathologically, it is very similar to the veno-occlusive disease, marked 
congestion with each lobule, also some necrosis in the affected area, which can result in 
the liver size decrease. Clinically, patients will feel tired, gain unnecessary weight, 
develop ascites and so on. Furthermore, these adverse effects may restrict the dose of 
antineoplastic therapy that can be administered or cause a delay in therapy, perhaps 
limiting the efficacy of treatment. 
  In recent years, a number of strategies have been developed to improve the outcome of 
intrahepatic cancer treatment. Besides the three dimensional treatment planning 
mentioned above which (combined with hepatic arterial FdUrd) has been successful for 
patients with fewer than 3-4 lesions, another strategy is the use of cytoprotective drugs to 
minimize or avert treatment-related toxicities to normal tissue. We hypothesize that the 
outcome of treatment can be improved further by the application of a radiation protector. 
Four groups of patients could benefit from this approach: 
1) Patients with diffuse gross disease: Although the ability to increase whole liver 







palliation for patients with gross disease who are often suffering from significant 
pain or other tumor related morbidity.  
2) Patients with occult intrahepatic disease: Clinical data suggest that an increase in 
whole liver dose to the 46-52 Gy that would be permitted by the use of a radiation 
protector could offer the opportunity to cure patients with occult intrahepatic 
disease. This dose of radiation prevents the recurrence of occult disease in head 
and neck cancer, lung cancer, gastric cancer, and rectal cancer. It is possible that 
even lower doses could be effective when administered concurrently with 
fluoropyrimidines, which are potent radiation sensitizers. 
3) Patients with focal liver disease: This is particularly true for patients who can 
safely receive doses in the range of 45-60 Gy without cytoprotectant. Although 
these doses can, in combination with hepatic arterial FdUrd, cause tumor 
regression, they have not produced the long-term survival, which has been 
experienced by patients who can receive ≥ 70 Gy. In this latter group, a median 
survival in excess of 16 months has been produced. Thus, the development of a 
selective radioprotection strategy could permit more patients with focal liver 
disease to derive the benefit of higher doses that, so far, have relied solely on 
technical improvements in delivery. 
4) Patients who develop VOD after treatment with high dose chemotherapy used in 
bone marrow transplantation evidence the identical pathologic lesion as those 
suffering from RILD. Thus, the development of a strategy that protects against 







The liver appears to be a particularly promising organ for a radioprotective strategy. If 
amifostine treatment allowed even a modest increase in the dose of radiation that can be 
tolerated by the whole liver, tens of thousands of cancer patients a year could benefit. A 
brief description of the liver anatomy and physiology, pathology of treatment-induced 
hepatic toxicity, and pharmacodynamics/pharmacokinetics of amifostine is provided 
below in order to better understand the limitations of chemo- and radiotherapy in the 
current treatment of hepatic carcinoma.  
2.1.1 Anatomy and physiology of the liver[8] 
  The liver is the largest metabolic organ in the body. It is divided into two lobes – a large 
right lobe and a smaller left lobe that merges in the middle. The basic functional unit of 
liver is the liver lobule, which contains specialized epithelial cells called hepatocytes, a 
network of interconnected plates around a central vein. Large vascular capillaries known 
as sinusoids form a reservoir of blood, facilitating drug and nutrient removal prior to 
entering the general circulation. The sinusoids are lined with endothelial cells, or Kupffer 
cells that engulf worn-out white and red blood cells and foreign substances from the 
blood.  
  The liver receives blood from the hepatic artery and the large hepatic portal vein that 
collects blood from different segments of the GI tract. The arterial blood from the aorta 
carries oxygen to the liver and accounts for about 25% of liver blood flow. The venous 
blood containing newly absorbed nutrients from the GI tract accounts for about 75% of 
liver blood flow. Within the liver, the terminal branches of the hepatic artery and portal 
vein mix with sinusoids. Blood leaves the liver via the hepatic veins, which join the 







2.1.2 Liver pathophysiology with radiotherapy 
  Radiation-induced liver disease (RILD), often called radiation hepatitis, is a syndrome 
characterized by the development of anicteric ascites approximately 2 weeks to 4 months 
after hepatic irradiation.[9] RILD resulting from liver radiation can usually be 
distinguished clinically from that resulting from the preparative regime associated with 
bone marrow transplantation. However, both syndromes demonstrate the same 
pathological lesion: veno-occlusive disease (VOD). Grossly, VOD is characterized by 
areas of marked congestion, which involve chiefly the central portion of each lobule. Foci 
of yellow necrosis may appear in the center of the affected areas. Although the 
pathological mechanism of VOD is still unclear, it appears that irradiation results in the 
accumulation of extensive deposits of fibrin in the liver central veins and in the afferent 
sinusoids. The fibrin deposits remain for a prolonged period of time, perhaps because the 
radiation has impaired the fibrinolytic mechanism. Eventually the long-standing fibrin 
deposits are invaded by fibroblasts and deposition of collagen occurs. RILD typically 
occurs 4-8 weeks after the completion of treatment in which patients present with fatigue, 
rapid weight gain and increased abdominal girth. Physical examination reveals ascites 
and hepatomegaly although, in mild cases, the signs are detectable only by ultrasound or 
abdominal CT scan. Serum chemistry shows moderate elevations of aspartate 
transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase. The chief 







2.2 Cytoprotectants against chemo- and radiotherapy induced cytotoxicities 
2.2.1 Cytoprotectants 
  Dose-limiting toxicity secondary to antineoplastic chemotherapy and/or radiotherapy is 
due to the inability of cytotoxic drugs to differentiate between normal and malignant 
cells. The consequences of this may include impairment of patient quality of life because 
of toxicity, and reduced tumor control because of the inability to deliver adequate dose-
intensive therapy against the cancer. Specific examples of toxicity against normal tissues 
include cisplatin-related neurotoxicity and nephrotoxicity, myelotoxicity secondary to 
treatment with alkylating agents and carboplatin, oxazaphosphorine-induced 
haemorrhagic cystitis, and cumulative dose-related cardiac toxicity secondary to 
anthracycline treatment. 
  The concept of site-specific inactivation of chemotherapy drugs and/or highly reactive 
electrophilic intermediates induced by radiation with cytoprotective agents has been 
extensively explored in both preclinical and clinical studies. The aim of cytoprotective 
agents is to improve the therapeutic ratio of the cytotoxic drug by reducing potential 
dose-limiting toxicity to normal tissue. By definition, cytoprotectants must not 
compromise the antitumor efficacy of the chemotherapy agent and radiation therapy, and 
they should not be associated with additional toxicity that might otherwise interfere with 
the delivery of adequate chemo- and radiotherapy. Consequently, the “ideal” chemo-
/radioprotector should have the following properties:[10] 
• Act selectively in normal tissues as opposed to tumor 







• Access normal tissues in adequate concentrations to elicit radiation modification 
or chemotherapy protection 
• Make a radiation/chemotherapy dose less effective to normal tissues by: 
1. Decreasing radiation-induced damage 
2. Scavenging free radicals 
3. Chemically “repairing” radicals induced by radiation/chemotherapy 
4. Enhancing enzymatic repair pathways 
5. Other mechanisms 
• Take into account the appropriate timing of drug delivery and 
radiation/chemotherapy treatment for maximal protection 
In principal, the ideal protector allows for a larger anticancer dose to be delivered to the 
tumor. It is important to remember that in many tumors, response to radiation or 
chemotherapy is dose-dependent; therefore, increasing the dose delivered to the tumor 
will increase the likelihood of tumor cure. 
  The first cytoprotectant to be used was folinic acid (calcium folinate; leucovorin), 
designed to overcome methotrexate-induced toxicity. Since that, several cytoprotective 
compounds have been extensively investigated, including dexrazoxane, glutathione, ORG 
2766, mesna and amifostine.[11] Among these compounds, the most noteworthy are 
dexrazoxane, mesna and amifostine because they have not only been approved by the 
FDA, but have also been routinely used, worldwide, in a clinical setting. 
  The anthracycline antibiotics, including doxorubicin (adriamycin), daunorubicin and 
epirubicin, are among the most active anticancer agents against a wide range of solid and 







appears to be associated with the generation of reactive oxygen species involving the 
formation of an anthracycline-iron complex, can limit effective clinical use of the above 
compounds. With this recognition, two promising metal-chelating agents have 
demonstrated a cardioprotective effect during acute and chronic treatment with 
doxorubicin and daunorubicin. One of them is razoxane (ICRF-159). Dexrazoxane 
(ICRF-187) is the more water soluble (+)-enantiomer of razoxane, which can be 
administered parenterally. The current FDA approval for dexrazoxane use is restricted to 
women with breast cancer who have already received 6 cycles of doxorubicin-based 
chemotherapy. 
  The oxazaphosphorine-based alkylating agents, including ifosfamide and 
cyclophosphamide, undergo metabolic activation by the hepatic microsomal enzyme 
system to form phosphoramide mustard and acrolein. Acrolein and other urotoxic 
metabolites are subsequently excreted intact into the urinary bladder to produce 
haemorrhagic cystitis. In the absence of a chemoprotective agent, ifosfamide and 
cyclophosphamide are associated with dose-limiting urothelial toxicity. Mesna (sodium-
2-mercapto-ethane sulfonate) has been developed as a specific chemoprotective 
compound against acrolein-induced bladder toxicity. 
  Dexrazoxane and mesna have a relatively limited spectra of toxicity protection (i.e., 
cardiac and urothelial, respectively), whereas amifostine appears to be a broad-spectrum 
selective cytoprotective agent that has a broader potential tissue-protection spectrum. A 
broad-spectrum selective cytoprotective agent can be defined as one that protects 
multiple normal organs from the toxicity of cytotoxic antineoplastic therapies without 







war by the Walter Reed Army Institute of Research (WRAIR) as part of a United States 
Army classified research project to identify an agent that could be used to protect military 
personnel and the population against atomic radiation in the event of nuclear warfare. Of 
4400 chemicals screened for this purpose, amifostine was selected as having the most 
effective radioprotective properties and a relative safety profile.[12] Further laboratory and 
clinical studies have shown that amifostine can protect a broad range of normal tissues 
and organs (e.g., bone marrow, peripheral nerve, heart, kidney, salivary gland and others 
with the exception of central nervous system) against the cytotoxic effects of alkylating 
agents, platinum compounds, anthracyclines, taxanes and irradiation without 
compromising antitumor cytotoxicity. To date, it is the broad-spectrum cytoprotective 
agent with the largest preclinical and clinical database. Based on both laboratory and 
clinical evidence, amifostine may be the most promising radioprotector for the liver.[13] 
2.2.2 Chemistry of amifostine  
  Amifostine (Ethiofos, WR-2721) is a low molecular weight (MW 214.2) thiophosphate 
ester prodrug. Amifostine is highly water soluble, with the solubility of the trihydrate 
being more than 9 g per 100 ml at room temperature. The compound has four ionizable 
groups, two of which are associated with the phosphate function and two with the amino 
function. At physiological pH, the drug exists as a double zwitterion with an isoelectric 
point of about 6.6. Amifostine is also very polar, with an octanol/water partition 
coefficient smaller than 0.01, indicating minimal octanol partitioning. Its free thiol active 
metabolite (WR-1065) has an octanol/water partition coefficient of 0.037.[14] Because 
passage of drugs through lipid membranes and interaction with macromolecules at 







drug, both amifostine and WR-1065 are orders of magnitude away from the lipoidal 
partitioning associated with good membrane permeability. 
  When administered intravenously, amifostine has shown to have good protection against 
radiation. However, after oral administration of the compound, a significant amount of 
the radioprotective activity of the compound is quickly lost,[12] perhaps due to an acid-
catalyzed hydrolysis of the ester bond in the stomach prior to absorption. The resulting 
WR-1065 is presumably further metabolized to inactive compounds resulting in a loss of 
radioprotective activity. Further detailed studies have indicated that amifostine is unstable 
at the gastric pH. The stomach pH ranges from 1 to 3, and amifostine is hydrolyzed to 
WR-1065 under acidic conditions. The hydrolysis reaction of amifostine, which appears 
to be pH- and temperature- dependent but nonenzymatic, proceeds by cleavage of the P-S 
bond to yield a thiol (WR-1065) and inorganic phosphate[15] 
(i.e., H2N(CH2)3NH(CH2)2SPO3H2 + H2O → H2N(CH2)3NH(CH2)2SH + H3PO4).  
The maximal rate of hydrolysis occurs at pH 3.0. However, at neutral pH, no detectable 
hydrolysis occurs over 4 hours at room temperature. The half-life for hydrolysis of 
amifostine at the low pH of stomach juice at physiologic temperature is about 30.5 
minutes. The hydrolysis reaction is also strongly temperature dependent. Cooling 
amifostine sample to 0°C minimizes the hydrolysis rate of amifostine to an acceptable 
rate even in highly acidic conditions. In the 1 M perchloric acid solution (pH<1) that is 
used to deproteinize blood samples containing amifostine and WR-1065, the rate of 
conversion is 0.6%/hr at 0°C. However, at room temperature the rate of hydrolysis in the 







  In studies with cells in culture, no detectable drug uptake or radioprotection can be 
found when cells were exposed to amifostine in medium alone, but when alkaline 
phosphatase was added to the medium efficient uptake leading to appreciable cellular 
levels of WR-1065 and radioprotection were observed.[16] Additionally, amifostine 
dephosphorylation in mouse alkaline phosphatase enzyme preparations was inhibited by 
vandate, an alkaline phosphatase competitive inhibitor. All these results support the 
hypothesis that alkaline phosphatase is the catalyst responsible for the hydrolysis of 
amifostine and subsequent uptake of WR-1065 by cells in vivo. Alkaline phosphatase is 
located in the plasma membrane surface of cells and is particularly rich in the endothelial 
cells of arterioles in various tissues, in the epithelial cells of the proximal tubule of the 
kidney, and in the microvilli of the small intestine. Studies of standard alkaline 
phosphatase substrate in rat jejunum and colon specimens localize alkaline phosphatase 
to the rim of the jejunal brush border and show negligible activity in the colon.[17] Human 
and mouse isoforms of alkaline phosphatase have a pH optimum between 8 and 9 with 
amifostine as the substrate. 
2.2.3 Detection of amifostine and WR-1065 
  Several serious obstacles have hampered the development of bioanalytical methods for 
amifostine. The compound is acid-labile, has no convenient chromophore, and has 
essentially no solubility in organic solvents because it is extremely polar. Lack of 
solubility in organic solvents precludes its extraction from biological fluids and its 
polarity places limitations on the types of chromatographic systems that might be used to 







biological matrixes presents a challenge since the thiol can rapidly be oxidized to form 
either symmetrical or non-symmetrical (with other endogenous thiols) disulfides. 
  In spite of these difficulties, direct and reliable measurements of amifostine and WR-
1065 in biological matrixes have been achieved in several laboratories using 
electrochemical detection coupled to liquid chromatography.[18,19] An amperometric 
electrochemical detector equipped with a thin film Hg/Au working electrode was used, 
and selectivity was enhanced by the use of a low electrode potential +0.15 V versus 
Ag/AgCl reference electrode. 
  In liquid chromatography with electrochemical detection (LCEC), analyte eluting from 
the analytical LC column undergoes electrolysis by passing over a planar electrode held 
at a fixed potential. If the potential is greater than that required for the electrolysis of the 
analyte, a measurable charge passes from electrode to analyte (or vice versa). The 
resulting current is directly proportional to the concentration of solute passing through the 
electrode. In terms of thiol detection with amalgamated gold electrode, the mechanism is 
presented by the following electrochemical oxidation reaction: 2RSH + Hg → Hg(SR)2 + 
2H+ + 2e-. The symmetrical disulfide (WR-33278) can be detected by using a dual 
electrode thin-layer cell in a series arrangement. The upstream electrode, held at –1.0 V 
vs Ag/AgCl, reduces the disulfides to the thiols which are detected downstream at +0.15 
V vs Ag/AgCl. Non-symmetrical disulfides are difficult to detect since they are formed 
by a variety of protein and/or other compounds that are available physiologically 
(example: cysteine, glutathione). Alternatively, the total amount of WR-1065-related 
species could be measured by reducing all disulfides bonds and then measuring the levels 







  Other published analytical methods for measuring levels of amifostine and WR-1065, 
especially for amifostine, are not direct and either use fluorescent derivatization 
(fluorescamine, monobromobimane) with the detection by fluorescence[20] or utilize the 
coulometric detector[21] which is believed to be more efficient than a traditional 
amperometric one. Unfortunately, analytical methods that involve conversion of 
amifostine to WR-1065 prior to analysis are indirect measures of amifostine, resulting in 
a more complicated validation process and perhaps less accuracy. 
2.3 Pharmacodynamic properties of amifostine 
2.3.1 Mechanism of action 
  Radiotherapy and chemotherapy are two main approaches in cancer patient treatment. 
Clinically, irradiation is derived from gamma (usually a 60Co or 137 Cs source), x-ray or 
neutron emissions in most situations, whereas an electron beam or beta irradiation is used 
sometimes. The much more energetic gamma rays and x-rays, like ultra-violet rays, can 
interact directly with the DNA molecule. However, they cause most of their damage by 
ionizing the molecules, especially water, surrounding the DNA and/or DNA itself. This 
forms free radicals, i.e., chemical substances with an unpaired electron. These free 
radicals, especially those containing oxygen, are extremely reactive and immediately 
attack neighboring molecules. When such a free radical attacks a DNA molecule, it can 
change a base, but it frequently causes a single- or double-stranded breakage. Single-
stranded breaks are ordinarily not serious because they are easily repaired by rejoining 
the ends of the severed strand. However, double-stranded breaks are very difficult to 
repair properly, so they frequently cause a lasting mutation. Additionally, chemotherapy 







formation of DNA-DNA interstrand crosslinks or platinum-DNA and platinum-protein 
adducts. 
  Amifostine is a prodrug that is dephosphorylated by the membrane-bound enzyme 
alkaline phosphatase, to form the free thiol metabolite, WR-0165. WR-1065 is the main 
metabolite responsible for the cytoprotective effects of amifostine and is the metabolite 
most readily taken up into cells. Once inside cells, WR-1065 provides protection from 
radiotherapy and/or chemotherapy through several mechanisms. They include the 
following: 
• WR-1065 can lower intracellular oxygen concentrations by competing with 
oxygen to prevent oxygen interactions with DNA radicals, which can generate 
potentially harmful hydroperoxides, resulting in fixation of damage and an 
increase in the risk of cell death.[22] 
• The oxygen-independent mechanism appears to involve radical scavenging, such 
as those derived from radiation therapy or specific drugs (e.g., doxorubicin-
derived superoxide anions), and/or hydrogen donation reactions.[23] 
• WR-1065 can not only bind directly, and thus detoxify the active species of 
alkylating agents[24] or platinum agents[25] in normal tissues, but also partially 
reduce DNA platination by the cytotoxic agent (formation of cispaltin-DNA 
adducts). 
• Some evidence indicates that both WR-1065 and amifostine can form complexes 
with cisplatin active species and detoxify them.[26] 
• WR-1065 exerts cytoprotective effects, in part, via a catalytic inhibition of the 







cells in G2 phase and to prolong the cell cycle, thus providing more time for DNA 
repair.[27] 
• The symmetric disulfide WR-33278, which is a metabolite of WR-1065, has 
cytoprotective properties as well. Those cytoprotective properties are explained 
by the structural similarities of the symmetrical disulfide to the polyamine 
speramine. WR-33278 binds more avidly to DNA than does speramine and 
enhances the relaxation of supercoiled DNA mediated by topoisomerase I.[28] 
• Post-treatment of irradiated cells with WR-1065 has been shown to markedly 
attenuate radiation-induced apoptosis. WR-1065 has also reduced apoptosis 
caused by several chemicals.[29] 
  The protective effects of amifostine are largely limited to normal, and not tumor, tissue. 
This selective protection is based on the ability of WR-1065 to be taken up in higher 
concentration in normal organs than in tumor tissues. This preferential uptake is due to a 
combination of several biological features. 
  First, drug delivery is significantly impaired in tumor as compared with normal tissue 
due to the poor vascularisation of most tumors. Furthermore, alkaline phosphatase, the 
membrane-bound enzyme responsible for the dephosphorylation of amifostine to WR-
1065, is largely distributed in capillaries and arterioles of normal tissues; however, solid 
tumors are poorly vascularised and tend to contain low levels of alkaline phosphatase. In 
normal human lung cells, alkaline phosphatase activity was found to be 275-fold higher 
than in non-small cell lung cancer cells. Consequently, less activation of amifostine to the 
active metabolite WR-1065 happen in tumor tissues because of lower levels of alkaline 







tissue may explain the selective protection of amifostine against cytotoxic chemotherapy 
and/or radiotherapy.[30] 
  Another factor which contributes to the selective protective effects of amifostine is the 
difference in pH between normal and tumor tissues. The relatively high pH of normal 
tissues is optimal for WR-1065 formation as well as WR-1065 uptake. Amifostine is not 
dephosphorylated by acidic phosphatase, so the acidic pH associated with many tumors 
may restrict both the formation and uptake of WR-1065. It was shown that a decrease of 
0.3 units in pH caused a two-fold reduction in the cell uptake rate of WR-1065. This 
means that even if WR-1065 does become available to tumor tissues it will not be 
absorbed by the cells at rate comparable to that of normal tissue.[31,32] 
  Finally, amifostine may be actively absorbed by normal tissue cells and only passively 
absorbed by tumor cells. As to the regional delivery of amifostine to the liver, which may 
offer more protection to the liver than systemic administration, it has been documented 
that the major source of blood flow to macroscopic hepatic cancers is by way of the 
hepatic artery. In contrast, the delivery of nutrients to normal tissues is primarily a 
function of the portal circulation. Thus, amifostine selectivity in liver may not only be 
enhanced by differences between normal tissue and tumor in alkaline phosphatase 
activity as described above, but also by differences in the drug’s regional route of 
delivery (i.e., portal vein is favored).[33] 
2.3.2 Protection against cytotoxic chemotherapy  
  The protective activity of amifostine against the tissue damaging effects of cytotoxic 







fluorouracil, lomustine, melphalan or oxidopamine) has been assessed in animal models 
and in patients with cancer. 
  In a preclinical study with mice,[34] amifostine has been shown to reduce cisplatin-
induced nephrotoxicity without interfering with the cisplatin antitumor effect. This study 
suggests that the protection offered by amifostine allowed a 2.2-fold increase in cisplatin 
dose to 19 mg/kg before the occurrence of nephrotoxicity, which resulted in an increased 
antitumor effect of cisplatin. Clinical trials[35-38] of amifostine in combination with 
cisplatin also demonstrated a significant protection from the nephrotoxicity and 
neurological toxicities associated with the use of cisplatin, without compromising its 
antitumor efficacy. In conclusion, amifostine may be considered for the prevention of 
nephrotoxicity in patients receiving cisplatin-based chemotherapy. 
  Neutropenia, consisting primarily of leukopenia, is the principal dose-limiting toxic 
effect of cyclophosphamide. An expert panel from the American Society of Clinical 
Oncology (ASCO) recommends that amifostine be considered for the reduction of 
neutropenia-associated events in patients who receive alkylating-agent chemotherapy.[39] 
Carboplatin toxicity differs significantly from that of cisplatin. The usual dose-limiting 
toxic effect of carboplatin is bone marrow suppression, particularly thrombocytopenia. 
Pretreatment with amifostine increased carboplatin maximum tolerated dose from 400 to 
500 mg/m2, without compromising its antitumor activity.[40] Pretreatment with amifostine 
has shown significant protection of bone marrow, immune system and intestinal crypt 








    Amifostine does not appear to affect tumor response to, or antitumor activities of, 
chemotherapy. Although amifostine may demonstrate tumor-protective effects under 
certain experimental conditions in a small number of early preclinical studies, the 
protection of tumor cells was typically low and variable, being dependent on dose, tumor 
type and size, and administration time. No evidence of tumor protection has been 
reported in clinical trials.[45] 
  Amifostine is generally well tolerated and is associated with transient side effects, 
including nausea, vomiting, a warm or flushed feeling and occasional allergic reactions. 
The most clinically significant toxicity is hypotension. Based on the recommendation by 
the American Society of Clinical Oncology (ASCO), the suggested dose of amifostine 
with chemotherapy in adults is 910 mg/m2, and is administered IV over 15 minutes, 30 
minutes before chemotherapy.[39] 
2.3.3 Protection against radiotherapy 
  A protective effect of amifostine against radiation has been convincingly demonstrated 
in mice, dogs and monkeys against x-, γ- and neutron-irradiation. Yuhas[46] demonstrated 
a dose-modifying factor (DMF; ratio of irradiation doses with and without amifostine 
required to produce a specific effect in 50% of animals at a given time) of 2.7 against 30-
day mortality in mice. Protection of dogs with amifostine was demonstrated at 200 
mg/kg, a dose producing one death due to drug, but five other animals survived the toxic 
effects of irradiation. At 150 mg/kg amifostine, a better tolerated dose, 8 of 16 dogs 
survived the toxic effects of irradiation. Rhesus monkeys were protected by 250 mg/kg of 
amifostine administered intravenously 30 minutes before irradiation.[12] While some 







preclinical data are available regarding intrahepatic cancers. Studies in rats[47,48]  have 
demonstrated that systemic administration of amifostine protects hepatocytes with a dose 
modification factor of 2, and that the liver is protected from fibrosis with a dose 
modification factor that is greater than 2. However, these studies did not determine 
whether the protection of normal liver extends to protection of tumor cells from the 
cytotoxic effects of radiotherapy. 
  Symon et al.[49] have recently evaluated whether systemic or portal venous 
administration of amifostine could protect the normal liver from the effects of ionizing 
radiation without compromising tumor cell kill in a rat liver tumor model. A 
micronucleus assay was used in this study and has been shown to be a sensitive measure 
of hepatocyte radiosensitivity. For instance, Alati et al.[50] have shown that the radiation 
dose response for the induction of micronuclei in hepatocytes is linear both in air and 
under hypoxic conditions. Rats implanted with liver tumors were infused with 200 mg/kg 
amifostine over 15 min via the femoral or portal vein. After a single 6-Gy fraction 
irradiation, the frequency of hepatocyte micronuclei after administration of saline, 
systemic amifostine and portal venous amifostine was 18.7 ± 1%, 6.8 ± 1% and 9.9 ± 2%, 
respectively, corresponding to a radiation equivalent effect of 6 ± 0.5 Gy, 1.8 ± 0.3 Gy, 
and 2.5 ± 1.3 Gy, respectively. Both amifostine conditions showed considerably less 
radiation effect than saline-treated control (p<0.01); the two amifostine conditions did not 
differ significantly (p=0.3). The surviving fraction of tumor cells was not affected by 
amifostine treatment and was 0.03 ± 0.02 and 0.05 ± 0.03 for systemic and portal venous 
delivery, and 0.06 ± 0.02 for control animals (p=0.34). These findings demonstrate both 







from ionizing radiation without compromising tumor cell kill in a clinically relevant 
animal model, and amifostine may be a selective normal tissue radioprotectant in liver 
cancer. 
  The possible benefits of using amifostine in combination with radiation therapy include 
reducing treatment-related toxicity and escalation of radiation dose in the curative 
treatment of cancer. Although several randomized clinical trials[51,52] have been 
conducted to determine amifostine protection in patients receiving radiation treatment for 
different cancers, its only approved use in combination with radiotherapy is as a protector 
against irradiation-induced xerostomia. This approval is based on the data from a large 
multi-center study in patients undergoing radiation therapy for head and neck cancer. 
Amifostine-treated patients demonstrated a statistically significant decrease in acute and 
chronic xerostomia compared to control patients. Another recent randomized trial in 
patients with lung cancer confirmed these results. Amifostine treatment significantly 
reduced pneumonitis and esophagitis, without decreasing tumor control. These and other 
clinical trials give strong support to the use of amifostine as a radioprotector. When given 
with radiation therapy for head and neck cancer, the recommended amifostine dose is 200 
mg/m2/day given as a slow IV push over 3 minutes, 15 to 30 minutes before each fraction 
of radiation therapy. 
  The liver appears to be a particularly promising organ for a radioprotective strategy 
using amifostine. As described previously, even a modest protective effect would permit 
a clinically meaningful increase in radiation dose to be delivered. In a small-scale study 
(internal protocol in progress), seven patients with diffuse intrahepatic cancer were 







mg/m2 of amifostine prior to each dose of radiation, with a plan of radiation dose 
escalation. Treatment was delivered with concurrent hepatic arterial FdUrd. No patients 
developed RILD. There were no episodes of hypotension and no ≥ grade 3 nausea. The 
median survival of all patients was 10 months. Another preliminary study[53] showed that 
19 of 203 patients treated with focal and whole liver radiation with amifostine 
pretreatment developed RILD without hepatic arterial FdUrd. From this study, patients 
with primary hepatobiliary cancers had a significantly greater risk of complication than 
those with colorectal cancer metastatic to the liver. These data suggest that amifostine 
administered systemically may protect the liver in patients with intrahepatic cancer who 
are undergoing whole liver radiation. 
  In summary, amifostine has the promise of being an effective radioprotector that could 
improve patient treatment outcomes and the quality of life. However, amifostine’s 
radioprotective potential has materialized only in the treatment of head and neck cancer. 
Carefully designed preclinical and clinical trials may help to broaden the use of 
amifostine, for example, in liver cancer patients. 
2.4 Pharmacokinetic properties of amifostine 
  The pharmacokinetic parameters of amifostine and WR-1065 in mice, rats, dogs, 
monkeys and humans are summarized in Table 2-1, 2-2 and 2-3. These results are 
discussed in more detail in the following sections below. 
2.4.1 Absorption 
  The intravenous (IV) formulation of amifostine, used in virtually all clinical studies, is 
the sole formulation currently used for amifostine therapy in cancer patients. There is an 







oral therapeutic agent can be administered more conveniently and used for the protection 
of critical body tissues against ionizing radiation. It might also protect human populations 
from the radiation hazards of nuclear events. However, oral administration of amifostine 
fails to protect monkeys and dogs, suggesting poor bioavailability of the drug. Besides 
the physicochemical properties of amifostine that have been described previously, 
various physiological factors such as gastric and intestinal transit time, drug binding, 
biotransformation in intestinal wall or liver are known to affect the rate and extent of 
amifostine absorption. It has been shown that amifostine suppresses stomach emptying 
and motility in the rhesus monkey.[54] Although the site of absorption of amifostine after 
oral administration is unknown, the main site of drug absorption is considered to be the 
small intestine. Another important cause of incomplete bioavailability of drugs is 
biotransformation in the intestinal wall or in the liver. When the extent of intestinal or 
hepatic extraction of the drug is high, only a small fraction of the drug absorbed from the 
intestine may actually reach the systemic circulation. 
  Characterization of amifostine and WR-1065 absorption in the rat small intestine[55,56] 
indicated that without an absorption enhancer (EDTA), a significant amount of parent 
compound (amifostine) was degraded in the small intestine presumably by 
dephosphorylation via alkaline phosphatase found in the brush border of the intestinal 
epithelium; WR-1065 was also extensively metabolized in the intestinal lumen and 
poorly absorbed. A decreased stability of amifostine and WR-1065 may increase the 
absorption of the radiolabeled compound, suggesting that the metabolites or degradation 
products of WR-1065 are better absorbed than the free thiol and parent compound. A 







different routes of administration (iv, intraduodenal, ip and portal), has shown that 
amifostine is not bioavailable after intraduodenal administration probably because of 
poor membrane permeability and metabolism by the intestinal tract and liver; low 
concentrations of free WR-1065 after intraduodenal administration revealed the drug’s 
poor oral bioavailability. 
  Levi et al.[59] characterized the tissue activation of amifostine by the liver, 
gastrointestinal tract, lungs, and kidneys after systemic administrations of amifostine 
using sequential dose rates of 0.125, 0.500 and 1.00 μmol/min/kg in dogs. The 
experimental results demonstrated that amifostine is eliminated more extensively by the 
liver than by the gastrointestinal tract, lungs, or kidneys. Approximately 90% of the drug 
is extracted by the liver (i.e., converted to WR-1065). It is clear that poor oral 
bioavailability of amifostine may be due to this large first-pass effect by the liver. A 
greater understanding of the absorption of amifostine and its primary active metabolite, 
WR-1065, may be gained by characterization of the sites and extent of this organ-specific 
activation with WR-1065 alone. 
  Clinically, the blood and/or plasma concentrations of amifostine and WR-1065 are 
undetectable after oral administration of amifostine to the healthy subjects.[60] The 
bioavailability for the oral route could not be determined and this route of administration 
was unsuitable for further studies.  
  In conclusion, amifostine’s poor bioavailability may have several explanations.  
Amifostine is readily hydrolyzed at gastric pH and suppresses gastric emptying. It is 







barriers found in the stomach and small intestine. Moreover, the small intestine and liver 
may be the sites of substantial drug metabolism. 
2.4.2 Distribution 
  Preferred distribution of amifostine and/or WR-1065 in healthy tissues compared to 
tumor tissues is important in explaining amifostine selectivity. Several studies[61,62] of the 
distribution of amifostine made use of radiolabelled drug (primarily [35S]-amifostine) and 
characterized the uptake of total [35S]-amifostine radioactivity (amifostine plus its 
metabolites) from the bloodstream of experimental animals (primarily rats). 
Biodistribution of 35S-labeled amifostine as a function of time after ip injection has 
shown that substantial tissue levels of 35S were attained by 15 min and peaked at 30 to 60 
min. The highest levels were obtained in kidney and submandibular salivary gland, with 
substantial levels in liver, gut, and lung. Whole brain and skin had the lowest levels of 
any normal tissues. A similar experiment using 35S-labeled amifostine demonstrated that 
the labeled compound is rapidly cleared from the blood and appears in high concentration 
in normal tissues and in low concentration in several tumors. The distribution half-life of 
[35S]-amifostine was very short - 5.5 min. The distribution of amifostine in normal tissues 
and tumors of rats, following both iv and ip injection, gave essentially identical results. 
Following administration (200mg/kg) of radiolabled amifostine, brain and spinal cord 
failed to accumulate detectable radioactivity over the 90-min test interval. In contrast, the 
lung, liver, heart and spleen initially contained less radioactivity than the serum, but by 
15 min postinjection their concentrations exceeded that of the serum by factors of 1.5 to 
2, indicating that these tissues are actively concentrating amifostine against a gradient. In 







tumors that were tested, radiolabel levels were significantly lower than in serum and 
slowly increased to equal decreasing serum concentrations 90 minutes after drug 
administration. From these observations, a facilitated transport process was suggested as 
the mechanism of uptake by the normal tissues studied versus passive absorption by 
tumors. 
  In a study of the distribution of WR-1065 after i.v. administration of 500 mg/kg 
amifostine to mice bearing tumors, Utley et al.[30] showed that maximal tissue 
concentrations of WR-1065 were achieved 5-15 min after injection. At 15 min after 
injection of [14C]- amifostine, WR-1065 accounted for more than half of the total drug in 
all tissues (liver, kidney, lung, heart, muscle, spleen and salivary gland) except the tumor, 
where it accounted for one third of the total drug. This study showed that WR-1065 is 
rapidly produced from amifostine, that it is a major metabolite of the parent drug, and 
that the rate of disappearance of WR-1065 from tissues is very rapid in some cases. 
Concentrations rapidly decreased during the first 30 minutes in the lung and skin, and 
more slowly in the liver, whereas concentrations remained high for up to 3 hours in the 
salivary gland. 
  In a study by Shaw and coworkers,[63] the highest WR-1065 concentrations were found 
in the liver and kidney (965 and 2195 μmol/kg, respectively) 10 min after i.p. 
administration of 365 mg/kg amifostine to mice bearing tumor. In contrast, the heart and 
small intestine had lower peak values of 739 and 410 μmol/kg, respectively, at 30 
minutes. Finally, WR-1065 accumulated in two experimental tumors at a significantly 
lower rate than it did in normal tissues. The pharmacokinetic behavior of amifostine was 







10-second bolus injection, there was a rapid biphasic decline in plasma drug 
concentration, with a distribution half-life of 0.88 minutes and an elimination half-life of 
8.76 minutes. After a 15-minute infusion in another study in which 740mg/m2 was 
administered to 10 patients with cancer, the average distribution half-life was 0.85 
minutes. In humans, amifostine has a relatively small volume of distribution steady-state 
of 6.44 L, suggesting that the unmetabolized drug is largely confined to the intravascular 
compartment (primarily plasma). The plasma protein binding of the drug is also low; in 
studies in vitro, less than 4% of radioactively labeled amifostine was bound to 
albumin.[65] 
  In a study by Symon and coworkers[49] to determine liver protection by systemic or 
portal venous administration of amifostine in rats bearing tumor, portal venous delivery 
produced significantly less WR-1065 in the tumor compared to systemic administration 
(54 μM ± 36 vs. 343 μM ± 88, respectively, p = 0.03) although the  levels of WR-1065 in 
the normal liver for systemic and portal venous delivery were found to be similar. This 
results in a significantly higher therapeutic index (i.e., mean liver/tumor concentration 
ratio) of WR-1065 for portal vein administration than for systemic venous administration. 
These findings support our hypothesis that compared to systemic administration, regional 
administration of amifostine may be advantageous in producing a higher normal to tumor 
WR-1065 ratio in liver.  
2.4.3 Elimination 
  Amifostine is hydrolyzed to the free thiol, WR-1065, via a non-reversible process. In 
turn, WR-1065 is further oxidized to form disulfides with itself, proteins with thiol 







disulfides is a reversible process. Moreover, it was hypothesized that the disulfides serve 
as a depot for WR-1065. WR-1065 can undergo oxidation to form sulfonic acid or N-
dealkylation to form cystamine. It was established in vitro that amifostine is 
dephosphorylated to form WR-1065, and that alkaline phosphatase is responsible for this 
process in several cell lines.[66] Following dephosphorylation, WR-1065 and the 
symmetrical disulfide (WR-33278) are then accumulated by cells in a ratio of 10:1, 
respectively. 
  Studies that investigated amifostine and/or WR-1065 metabolism have been conducted 
in mice,[55,56,63] dogs,[59,67,68] monkeys[57,58] and humans.[64,69,70] All these mammalian 
species share the similar extensive and rapid clearance of amifostine from the 
bloodstream as reflected by the short elimination half-lives observed. In monkeys,[57,58] 
conversion of amifostine to the thiol proceeded extremely rapidly since the peak 
concentration of WR-1065 occurred immediately after termination of the infusion of 
amifostine. Moreover, AUC values of amifosine and WR-1065 could account for only 
half of the radiolabel AUC values, suggesting the presence of unidentified metabolites in 
the plasma. In addition to WR-1065, several drug-related species were identified as 
metabolites of the parent drug and were present in the tissues of mice: they included WR-
33278, the symmetrical disulfide of WR-1065 and the mixed disulfides (WR-1065-
cysteine and WR-1065-glutathione). 
  In the study[59] in dogs to characterize the various tissues’ activation of amifostine 
described previously (i.e., 0.125, 0.500 and 1.00 μmol/min/kg), the hepatic extraction of 
amifostine remained high at 90%, whereas gastrointestinal extraction decreased from 43 







whereas renal extraction was intermediate at 57%. Approximately 90% of the drug is 
extracted by the liver (i.e., converted to WR-1065), suggesting that the liver may 
preferentially take up the active free thiol and be protected extensively against the 
toxicities of radiation. Based on the clearance parameters above, amifostine exhibits 
saturable metabolism in the gastrointestinal tract (9.8 to 2.8~3.3 ml/min/kg) and the 
whole body (52.6 to about 37.3 ml/min/kg) as the doses increased in dogs. It is also worth 
notice that amifostine has a minimal extraction by the gastrointestinal tract (i.e., less than 
15%) at concentrations likely to be achieved during clinical dosing. These conclusions 
formed the basis on which the study of liver radioprotection by regional delivery of 
amifostine is proposed.  
  In another metabolic study of amifostine,[71] it was found that small quantities of 
cysteamine were produced in mouse tissues following amifostine administration. 
However, cysteamine was not present in the blood 30 minutes after amifostine 
administration. These results support the hypothesis that WR-1065 undergoes N-
dealkylation to form cystamine. A disposition study of WR-1065 in monkey[58]  showed 
that free WR-1065 AUC values accounted for only 18.2% of the total WR-1065 AUC 
values, indicating rapid binding to endogenous thiols. It is further demonstrated that 
disulfide formation is a reversible reaction by measuring free WR-1065 levels in plasma 
following the administration of the symmetrical disulfide (WR-33278) to a beagle 
dog.[67,68] 
  The pharmacokinetics of amifostine in human have similar characteristics to that of 
animal models.[64,69,70,72]  For example, amifostine and the free active thiol metabolite 







is responsible for the clearance of amifostine from the blood stream with immediate 
conversion to WR-1065. Finally, amifostine demonstrates nonlinear kinetics. In patients 
who received 150 mg/m2 of amifostine intravenously, the elimination half-life is 8.76 
minutes and less than 6% of the parent drug remained in the plasma compartment within 
6 min after drug administration. AUC values for patients who received the 910 mg/m2 
dose (3,852 ± 1,363 μmol/min/L) are 2.6-fold higher than the values obtained for patients 
who received the 740 mg/m2 dose (1,506 ± 665 μmol/min/L). The expected ratio for 
linear pharmacokinetic behavior is 910/740 =1.23, suggesting that amifostine exhibits 
nonlinear kinetic behavior.[72] 
  Only small amounts of amifostine and its metabolites are excreted in the urine.[70] In 7 
patients receiving a 15-minute infusion of amifostine 740 mg/m2, the average of 
percentage of the total administered amifostine dose recovered in the urine after 45 
minutes was 1.05, 1.38 and 4.2% for amifostine, WR-1065 and WR-33278, respectively. 
Similar amounts of amifostine and metabolites (< 3% of the administered dose) were 
found in the urine after 45 minutes in 6 patients receiving a 150-mg/m2 bolus dose of 
amifostine.[64] The rapid elimination, small volume of distribution, and limited amount of 
drug and metabolites recovered in the urine suggest that amifostine is rapidly 
dephosphorylated and then enters cells as WR-1065. 
2.4.4 Drug-Drug interaction 
  The rapid elimination of amifostine from the plasma reduces the potential for drug 
interactions with antineoplastic agents, which are administered ≥ 15 minutes after 







some chemotherapeutic agents, although the clinical significance of these changes is 
either minimal or not yet determined. 
  In patients receiving carboplatin (400 or 500 mg/m2) or cisplatin (70 mg/m2) 
therapy,[73,74] pretreatment with amifostine (910-740 mg/m2) appears to reduce the renal 
clearance of these drugs. Mean values of the pharmacokinetic parameters of three 
cisplatin species (total, non protein-bound, and unchanged platinum) after treatment with 
and without amifostine indicate that amifostine had only a minor influence on the 
pharmacokinetics of cisplatin in plasma, resulting in an increase in the terminal half-life 
of cisplatin that is not protein-bound (0.77 hr with amifostine vs. 0.57 hr without 
amifostine). This effect was hypothesized to be due to a direct effect of amifostine on 
kidney function, because a transient increase in serum creatinine levels was observed in 
patients receiving the drug. 











(IV 10min, n=4) 
Monkeys[67] 
(IV 10min, n=5) 
Dose 150 mg/kg  120-150 mg/kg  
T1/2 T1/2(β) : 16.0 min T1/2 : 8-15 min 
Cmax 800-900 μg/ml 477 μg/ml 
Vd 120 ml/kg  



















Table 2-2:  Pharmacokinetic parameters of WR-1065 in dogs and monkeys ( X ± SD) 
 





            Dogs[67] 
            (n=3) 10-Min infustion 
     (n=3) 
120-Min infustion 
      (n=3) 
Dose  
        38.8 mg/kg 
        (IV 10min) 
 






           81.4 min 
 
           207 min 
 





             0.532 ± 0.226 
 
 
       0.375 ± 0.877 
 
 






              2.27 ± 0.898 
 
 
          3.02 ± 2.42 
 
 




               64 ± 6.9 
 
 
          64.1 ± 7.17 
 





           117 ± 13.8 
  





Table 2-3 Pharmacokinetic parameters of amifostine in humans ( X ± SD) 
 
 




(IV 10s, n=13) 
200 mg/m2 
(IV 7.5min, n=12)  
740 mg/m2
(IV 15min, n=10)  
740 mg/m2
(IV 15min, n=5) 
910 mg/m2 
(IV 15min,n=7) 
Vd (L) Vc : 3.50 ± 0.90 
Vss: 6.44 ± 1.46  
  8.7 ± 2.7 7.4 ± 2.2 
T1/2 
(min) 
T1/2(α) : 0.88 ± 0.12  
T1/2(β) : 8.76 ± 2.03  
 
15.4 ± 9.6 T1/2(α) : 0.85 1.5 ± 0.4  2.7 ± 0.8 
Cmax (μmol/L)  104.9 ± 30.9  100 ± 44 235 ± 77 
CL (L/min) 2.17 ± 0.39  1.48 ± 0.46  4.3 ± 1.8 2.1 ± 0.8 
AUC 
(μmol/min/L) 








2.64 ± 1.18  1.38   
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DETERMINATION OF AMIFOSTINE AND WR-1065 IN BLOOD/PLASMA AND 
TISSUE SAMPLES BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPH 
COUPLED WITH ELECTROCHEMICAL DETECTOR 
 
                                                                Abstract  
In order to measure the concentrations of amifostine and WR-1065 (i.e., active metabolite 
of the cytoprotective agent amifostine) in blood/plasma and/or tissue (liver, tumor) 
samples, a high-performance liquid chromatographic method coupled with 
electrochemical detectors (amperometric vs coulometric) was validated in our lab. 
Plasma samples containing prodrug amifostine were deproteinized by using 
trichloroacetic acid followed by chromatographic analysis using a mercury/gold thin film 
electrochemical detection liquid chromatography system. The limit of quantification of 
amifostine in plasma was 0.5µM. The amifostine to internal standard (WR-80855) peak 
height ratios were linear over the amifostine concentration range of 0.5 to 50 µM (R2 = 
0.999). With the same detector, WR1065 can be measured in deproteinized blood and/or 
tissue samples by perchloric/EDTA solution. In addition to that, WR1065 can also be 
determined by HPLC with coulometric detection (analytical cell: E1=200mV and E2=600 
mV; guard cell: EG=650mV). The limit of quantification of WR1065 in deproteinized 
blood was 0.05 µM. The WR1065 peak heights were linear over the WR1065 







investigating the pharmacokinetic properties of amifostine and WR-1065 in preclinical 
and clinical studies. Furthermore, the application of a coulometric electrode is more 
efficient and requires less maintenance than amperometric methods. 



































Amifostine [H2N(CH2)3NH(CH2)2SPO3H2; MW = 214] is a cytoprotective agent that is 
currently used to reduce the renal toxicity of cisplatin in patients with advanced ovarian 
cancer or non-small cell lung cancer, and to reduce the incidence of moderate to severe 
xerostomia in patients undergoing radiation treatment for head and neck cancer [1]. To 
offer protection, amifostine is effective only after it has been dephosphorylated by 
alkaline phosphatase in tissues to its pharmacologically active metabolite, WR-1065[2] 
[H2N(CH2)3NH(CH2)2SH; MW = 134]. To better understand the pharmacokinetic–
pharmacodynamic properties and relationship of amifostine and WR-1065, it is important 
to have an assay method that is accurate, precise and sensitive. In terms of thiols’ 
detection, it is necessary that biological specimens are collected and processed in a 
manner that assures drug stability because the thiol can rapidly be oxidized to form 
disulfides. Both amifostine and WR-1065 are not very stable in biological specimens 
because it rapidly forms inactive disulfides. Moreover, they are small, hydrophilic 
compounds with properties that are similar to that of endogenous free thiols. Thus, it is a 
challenge to specifically and sensitively measure both amifostine and WR-1065 in 
biological matrices.  In this specific study, both amifostine and WR-1065 are analyzed 
using high-performance liquid chromatography (HPLC), coupled to electrochemical 
detection [3, 4, 5, 6, 7, 8]. 
The principle of electrochemical detection of eluted solutes in high performance liquid 
chromatrography (HPLC) is similar to many other analytical electrochemical techniques: 







and the current is directly proportional to the concentration.  We used both amperometric 
and coulometric types of electrochemical detector to measure concentration of amifostine 
and/or WR1065 in biological samples.  An amperometric detector is a detector equipped 
with a thin film Hg/Au working electrode together with a Ag/AgCl reference electrode. 
When the thiols pass the surface of the electrode, the reaction 2RSH + Hg → Hg (SR)2 + 
2H+ will happen on the surface of the working electrode to genetrate the current which 
can be recorded by HPLC system.  A coulometric detector consists of dual analytical cell 
contains two porous graphite electrodes in series.  Typical designs of these two kinds of 
LCEC detector were shown on Fig 3.1. Comparison of efficiency and features of these 
two detectors was also done in this study. 
The HPLC methods were validated for assay of amifostine and WR-1065 in human blood 
samples and tissue sample, where biological samples were deproteinized by acidic buffer 
and 20 μl aliquot of supernatant was injected into HPLC after centrifuging, the method 
was specific, sensitive (limit of quantitation = 0.05 µM in deproteinized blood or 0.1 µM 
in whole blood for WR1065; and 0.5µM for amifostine in plasma), accurate (error ≤ 7.4 








                                                   Materials and Methods  
3.1. Chemical and reagents  
Amifostine and WR-1065 standards were generously provided by the Drug Synthesis and 
Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment 
and Diagnosis, National Cancer Institute (Bethesda, Maryland). Perchloric acid 70% 
(redistilled) was obtained from the Aldrich Company (Milwaukee, WI). EDTA disodium 
salt was purchased from the Sigma Chemical Company (St. Louis, MO). HPLC grade 
acetonitrile, water, phosphoric acid and trichloroacetic acid were purchased from Fisher 
Scientific (Pittsburgh, PA). Other chemicals were obtained from standard sources and 
were of the highest quality available.  
3.2. Sample processing  
3.2.1. Amifostine in plasma by amperometric detector 
Whole blood samples were immediately placed in prechilled Vacuette® EDTA tubes and 
centrifuged at 3400 g and 0~4°C for 5~10mins, and plasma was separated and stored at -
70°C for subsequent analysis. On the day of analysis, the plasma samples were thawed, 
WR-80855 was added as an internal standard, an aliquot of 10% (w/v) trichloroacetic 
acid was then added to an aliquot of the sample in the ratio of 2 to 5 (v/v) to precipitate 
the plasma proteins. Samples were mixed together thoroughly and centrifuged at 40,000g 
for 3 mins at 0°C. A 20 µl aliquot of supernatant was injected into the HPLC.  
3.2.2. WR1065 in whole blood by amperometric detector 
Aliquots of whole blood were immediately placed in prechilled tubes containing an 
equivalent volume of 1M perchloric acid and 1g/L EDTA solution in order to precipitate 







centrifuged at 20,000 g for 5 mins at 0~4 °C. WR-251833 was added as an internal 
standard into the supernatant. A 20 µl aliquot of supernatant was injected into the HPLC. 
3.2.3. WR1065 in tissue (liver and tumor) by amperometric detector 
Liver and tumor samples were dissected, weighted and frozen rapidly by putting them in 
a liquid nitrogen bath for 1~3 min. The samples were stored at -70 °C for subsequent 
analysis. On the day of analysis, the samples were homogenized (1:5, w/v) in an ice-cold 
deproteinizing solution containing 1.0 M perchloric acid and 2.7 mM (1 g/L) disodium 
EDTA. The homogenate was then centrifuged at 40,000 g for 5 mins at 0°C and WR-
251833 was added as an internal standard into the supernatant. A 20 µl aliquot of 
supernatant was injected into the HPLC.  
3.2.4. WR1065 in human whole blood by coulometric detector 
The whole blood samples were placed into prechilled tubes, containing ice-cold 1.0 M 
perchloric acid and 2.7 mM (1g/L) EDTA in a ratio of 1:1 (v/v), immediately after 
sampling. The mixture was then vortexed vigorously and centrifuged at 13,000 g for 8 
mins at 4 °C. The supernatant was stored at -70 °C for subsequent analysis. On the day of 
analysis (less than 24 hrs), the samples were thawed, and a 20 µl aliquot of supernatant 
was injected into the HPLC.  
3.3. Instrumentation  
3.3.1. Amifostine in plasma by amperometric detector 
The measurements of concentration of amifostine in plasma were performed on a Waters 
(Milford, Massachusetts) 515 isocratic HPLC pump. Amifostine and the internal standard 
WR-80855 were detected by a BAS (West Lafayette, Indiana) LC-4C amperometric 







electrode potential was set at +0.15V with respect to the Ag/AgCl reference electrode and 
the range of the detector was set at 20nAFS. The analytical column, 4.6×250mm, 5μm 
particle size, C18 Symmetry® Waters (Milford, Massachusetts), was operated at room 
temperature. The amifostine chromatography protocol consists of an aqueous mobile 
phase containing 0.1M chloroacetic acid sodium salt and 1.5mM sodium octyl sulfate, pH 
3.0 at a flow rate of 1ml/min. Peak identification was confirmed by comparing retention 
times in samples with authentic standards. Quantification was based on the peak height 
ratio of the compound and the internal standard. 
3.3.2. WR1065 in whole blood by amperometric detector 
The measurements of concentration of WR1065 in blood were performed on a Waters 
(Milford, Massachusetts) 515 isocratic HPLC pump. WR1065 and the internal standard 
WR-251833 were detected by a BAS (West Lafayette, Indiana) LC-4C amperometric 
detector equipped with a thin film mercury-gold amalgam working electrode. The Hg/Au 
electrode potential was set at +0.15V with respect to the Ag/AgCl reference electrode and 
the range of the detector was set at 50nAFS. The analytical column, 4.6×250mm, 5μm 
particle size, C18 Symmetry® Waters (Milford, Massachusetts), was operated at room 
temperature. The WR1065 chromatography protocol consists of a mobile phase 
containing 0.1M chloroacetic acid sodium salt and 1mM sodium octyl sulfate, pH 3.0, 
and 30% (v/v) methanol at a flow rate of 1ml/min. Peak identification was confirmed by 
comparing retention times in samples with authentic standards. Quantification was based 
on the peak height ratio of the compound and the internal standard. 







The measurements of concentration of WR1065 in tissue were performed on a Waters 
(Milford, Massachusetts) 515 isocratic HPLC pump. WR1065 and the internal standard 
WR-251833 were detected by a BAS (West Lafayette, Indiana) LC-4C amperometric 
detector equipped with a thin film mercury-gold amalgam working electrode. The Hg/Au 
electrode potential was set at +0.15V with respect to the Ag/AgCl reference electrode and 
the range of the detector was set at 0.1µAFS. The analytical column, 4.6×250mm, 5μm 
particle size, C18 Symmetry® Waters (Milford, Massachusetts), was operated at room 
temperature. The WR1065 chromatography protocol consists of a mobile phase 
containing 0.1M chloroacetic acid sodium salt and 1mM sodium octyl sulfate, pH 3.0, 
and 30% (v/v) methanol at a flow rate of 1ml/min. Peak identification was confirmed by 
comparing retention times in samples with authentic standards. Quantification was based 
on the peak height ratio of the compound and the internal standard. 
3.3.4. WR1065 in human whole blood by coulometric detector 
The WR1065 was detected by an ESA Coulochem III coulometric detector (Chelmsford, 
Massachusetts) equipped with two porous graphite electrode in series which are set at 
+600mv (E2) and +200mv(E1) respectively vs α-hydrogen/palladium reference electrode. 
The detector’s range is set at 5μAFS. The analytical column, 4.6×250mm, 5μm particle 
size, C18 Symmetry® Waters (Milford, Massachusetts), was operated at 40°C. The WR-
1065 chromatography protocol employed a mobile phase containing 0.1M chloroacetic 
acid sodium salt, 4mM sodium octyl sulfate, pH 3.0, and 40% (v/v) methanol running at 
1ml/min. Peak indentification was confirmed by comparing retention times in samples 








3.4. Calibration standards and quality controls 
3.4.1. Standard solutions 
The amifostine stock solution was made by dissolving 10 mg (100 mg) of amifostine in 
10 ml (100 ml) water. The WR1065 stock solution was made by dissolving 10 mg of 
WR1065 in 10 ml 0.2 M perchloric acid/0.1 M chloroacetic acid (v/v: 3/1, adjust pH from 
0.9 to 3 with 10 N NaOH) to prepare the standard stock solution of 1 mg/ml. The above 
stock solutions can be stored at −80 °C for at least one week.  
For both amifostine and WR1065, 100 µl of 1 mg/ml stock solution diluted with the 
solution for its stock solution to 1 ml to prepare the working solution of 100 µg/ml (0.1 
mg/ml), 20 µl (10 µl) of 1 mg/ml stock solution diluted with the solution for its stock 
solution to 1 ml to prepare the working solution 20 µg/ml (10 µg/ml), 200 µl of 10 µg/ml 
(100 µl of 20 µg/ml) diluted with the solution for its stock solution to 1 ml to prepare the 
working solution 2 µg/ml, 100 µl of 2 µg/ml diluted with the solution for its stock 
solution to 0.5 ml to prepare the working solution 0.4 µg/ml.  
Amifostine calibration standards were prepared at the time of assay from the 10 µg/ml, 
0.1 mg/ml and 1mg/ml aqueous working solution by making dilutions with blank plasma 
(~ 0.5ml) to obtain calibrators for the standard curve: 0.5, 1, 5, 10, 20, 50 µM. WR1065 
calibration standards were prepared from 20 µg/ml, 2 µg/ml and 0.4 µg/ml working 
solution of WR1065 by making dilutions with blank deproteinized blood (~ 0.1ml) to 
obtain calibrators for the standard curve: 0.048, 0.0966, 0.24, 0.48, 2.4, 9.66 µM.  
Stock solution of internal standard WR251833 was prepared by dissolving 5 mg of 
WR251833 in 5 ml aqueous solution containing 10 mmol/L Tris (M.W. 121.1), pH 7.4 







Working solution of 0.1 mg/ml and 20 µg/ml were prepared with 100 µl of 1 mg/ml stock 
solution diluted with the solution for its stock solution to 1 ml and 50 µl of 0.1 mg/ml 
solution diluted with the solution for its stock solution to 0.5 ml respectively. We fixed 
the concentration of internal standard WR251833 in WR1065 assay in deproteinized 
blood (~ 0.1ml) as 1 µg/ml and concentration of internal standard WR80855 in 
amifostine assay in plasma (~ 0.5ml) as 2 µg/ml.  
Calibration data were best fitted to a power function described by the equation: 
ln(Y) = slope · ln(X) + y-intercept, where (Y) is the peak height ratio of the amifostine or 
WR1065 and the internal standard or peak height of the compound and (X) is the 
concentration of the compound. Regression parameters (i.e., slope and y-intercept) were 
then used to calculate the concentration of WR-1065 in quality control samples and in 
vivo blood samples.  
3.4.2. Quality control and assay validation 
Amifostine and WR1065 quality control samples were prepared at the time of the 
analysis with blank plasma for amifostine at concentrations of 1, 10, 50µM or 
deproteinized blood for WR1065 at concentrations of 0.0966, 0.4831, 9.66 µM. The 
procedures developed for the quantitation of these two compounds were validated over 3 
days by analysis of quality control samples to determine within- and between-day 
precision and accuracy.  The limit of quantitation were defined as the ratio of signal-to-









Representative chromatograms of WR-1065 in deproteinized blood (with and without 
spiked compound) by amperometric detector are shown in Fig 3.2. Representative 
chromatograms of amifostine in plasma (with and without spiked compound) by 
amperometric detector are shown in Fig 3.3. For all of these measurements, no 
chromatographic peaks of the amifostine or WR1065 adduct were observed in blank 
plasma or deproteinized blood, indicating that endogenous compounds do not interfere 
with the compound to be detected with this method. Spiked samples clearly show a clean 
separation of WR-1065 or amifostine from the endogenous peaks that elute within 5 min 
after the injection. For those blood samples that were beyond the linear concentration 
range of quantitation, further dilution was achieved using blank plasma or blank 
deproteinized blood.  
Assay validation  
Standard curves of WR-1065 were linear over the 0.05–9.66 µM concentration range 
when prepared in deproteinized blood, as shown by the representative example in Fig 3.4. 
Assay validation on calibration standards of amifostine was presented in Table 3.1.  
Standard curves of amifostine were linear over the 0.5-50 µM concentration range when 
prepared in plasma, as shown by the representative example in Fig 3.5. Assay validation 
on calibration standards of WR1065 was presented in Table 3.2. Table 3.3 contains the 
mean results of WR-1065 quality control samples in deproteinized blood at three 
different concentrations (i.e., low, medium and high). Table 3.4 contains the mean results 
of amifostine quality control samples in plasma at three different concentrations (i.e., low, 
medium and high). Five replicates were evaluated within a day as well as two replicates 







good for the specific concentrations studied. Accuracy was represented by the percent 
relative error (%RE) of calibrations standards and quality control samples from their 
theoretical values using the Equation 2.1. 
%RE = (ConcentrationObserved –ConcentrationSpiked)/ConcentrationSpiked × 100    Eq. 2.1 
Precision was evaluated by percent relative standard deviation (%RSD), which was 
calculated using Equation 2.2. 
%RSD = Standard Deviation/Mean × 100                                                            Eq.2.2  
 In all cases, CV was ≤ 6.9% and error was ≤ 7.4%, regardless of whether the 
determinations were made intraday or interday.  
Discussion  
Most published HPLC assays for WR-1065 have been based on electrochemical [5, 6, 8] or 
fluorescent detection [3, 4, 7, 9]. Because both amifostine and WR1065 are thiols, 
electrochemical detection was used mostly to directly measure concentrations of 
amifostine and WR1065 in biological samples in literature. Because electrochemical 
detector was used in this specific analysis, some electrolytes need to be included in the 
mobile phase. Literaturely, 0.1M chloroacetic acid was used as electrolytes in mobile 
phase, then adjust pH of aqueous phase to 3.0 with sodium hydroxide. However, we 
didn’t get satisfactory chromatogram with these components in mobile phase. Because 
the aim is to form buffer system in the mobile phase, we changed to 0.1M chloroacetic 
acid sodium salt as electrolyte in mobile phase, then adjust pH of aqueous phase to 3.0 
with phosphoric acid. We tried different acids to adjust pH value, and found both 
phosphoric and hydrochloric acid could generate good peak shape, but phosphoric acid 







concentration of sodium octyl sulfate which is an ionpair agent in the mobile phase, this 
ability was indicated in the assay of different types of biological samples. The detailed 
mechanism of different mobile phase system need to be investigated, probably larger 
capacity of buffer system was formed with 0.1M chloroacetic acid sodium 
salt/phosphoric acid combination compared with 0.1M chloroacetic acid/sodium 
hydroxide system. Because amifostine is more polar than its active metabolite WR1065, 
we use pure aqueous mobile phase to control reasonable retention (6~7 min) compared 
with aqueous/organic phase mixture for the mobile phase of WR1065 analysis.  
A significant advantage of electrochemical detection is the simple biological samples 
processing before injection into HPLC. Generally, liquid-liquid or solid-phase extraction 
can be used for lipophilic or hydrophilic compounds respectively, however, extraction 
procedure always involve multiple steps including extraction, condensation and so on. 
For unstable compounds, extraction is not very appropriate because we want inject this 
compound into HPLC column as soon as possible. Another biological samples processing 
method, that is, direct injection was used in this specific assay. As to the method of direct 
injection, plasma and/or blood proteins are first precipitated by acids or organic solvents, 
then supernatant will be injected into HPLC column after mixing and centrifuging. The 
success of this method will be dependent on the sensitivity of the detector and efficiency 
of protein precipitation. Electrochemical detector has higher sensitivity compared with 
UV and fluorescent detector, so the key point for this assay is to select appropriate 
solvent to precipitate the plasma protein as complete as possible to make chromatogram 
clear and longer life of analytical column. People from literatures use organic solvent 







literatures, we found serious interference with the compound we need detect and the 
amount of protein precipitated by acetonitrile is small and the color of protein 
precipitated appears reddish compared with protein precipitated by strong acid. It was 
reported[10] that for unit volume of plasma, the percentage plasma protein precipitated by 
0.2 volume of 10% (w/v) trichloroacetic acid (TCA) is 99.7%; but only 13.4% by 
acetonitrile under same condition, the percentage plasma protein precipitated can reach 
97.2% by acetonitrile until an equivalent volume of acetonitrile was added to the plasma 
(1:1). Based on this result from literature, we won’t have lower limit of quantitation if we 
need precipitate the plasma protein as complete as possible by acetonitrile because we 
need add large volume of acetonitrile into plasma to precipitate the protein completely. 
We tried and selected 10% (w/v) TCA as protein precipitant in the assay of amifostine 
because it has much better efficacy of protein precipitation than that of acetonitrile. The 
only shortcoming of TCA precipitant is the acidic condition of supernatant (pH ~ 2.0) 
compared with that by acetonitrile precipitant (pH ~ 9.0) because amifostine is not very 
stable under acidic condition. In order to shorten the time amifostine stay in the acidic 
condition, we processed the plasma sample of amifostine right before the HPLC analysis 
and the results indicated that amifostine is detectable in plasma to 0.5 µM. From the 
literature report and analytical experience with WR1065 samples from our lab, we 
realized that significant degradation of WR-1065 occurs during sample preparation and 
storage (i.e., rapid oxidation while in plasma or blood), even at temperatures as low as 
−70 °C. Because WR1065 is relatively stable under acidic and low-temperature condition 
from the literature, as a result, blood samples containing WR1065 should be placed on ice 







EDTA to precipitate the protein and damage some enzymes and oxidative substances to 
stabilize the WR1065 as much as possible. In addition to that, samples should be 
analyzed for WR-1065 within 12~24 h of collection. Concentration of perchloric acid in 
this deproteinizing solution will be dependent on the presence of a clear supernatant and 
more acidic condition achieved by higher concentration of perchloric acid. EDTA was 
used to bind with metal ion in the biological samples to lower the oxidative condition 
which results in the formation of disulfides from WR1065. 
As to the electrochemical detector, the current generated depends upon concentration, 
fluid velocity, cell geometry, and electrode area for a given solute. Efficiency of 
electrochemical detectors for HPLC is strictly a matter of geometric design. A variety of 
flow-through electrochemical cells was developed and described theoretically. These 
include several basic geometries in LCEC detector design; tubular, thin layer, wall jet and 
coulometric porous. In our lab, we have two kinds of electrochemical detectors, one is 
thin-layer amperometric detector with which the solute flow over the surface of Hg/Au 
electrode, and reaction of 2RSH + Hg → Hg (SR)2 + 2H+ occurs. Based on this geometry 
of design and detection mechanism, that the efficiency of ampermetry which measures 
probably 15% of the electroactive species, should be less than real flow-through type of 
detectors results in the low intensity of the signal. However, because thiols will react with 
mercury on the electrode, the potential on the electrode should be low which can result in 
the less interference with the compound. Another is porous coulometric type of detector 
with which the solute flow through the porous graphite electrodes in series, and reaction 
of 2RSH → RSSR + 2e- + 2H+ occurs. Based on this type of geometry of design and 







the potential will be higher to induce that reaction which can probably result in more 
interferences in blank samples. However, the most important reason to make coulometric 
type is generally superior is much less maintenance work required for electrode compared 
with amperometric type. For this particular Hg/Au working electrode in amperometric 
detector, it is extremely difficult for novices to make results of assay reproducible 
because we need manually handle, polish and amalgamate the gold working electrode 
before and after each time of analysis. But once people get more experience with this 
type of detector, it is not a bad choice because low potential used with this type of 
detector can limit the number of endogenous substances oxidized or reduced. To some 
extent, the choice of different types of electrochemical detectors will be dependent on the 
time of developing the analytical method with the detector in hands.         
 In conclusion, we have described and validated an HPLC-electrochemical detection 
method for the measurement of amifostine and WR-1065 in biological samples. This 
method is specific, accurate, reproducible, and simple. With minor modifications of the 
published literature method, we have improved sensitivity compared with same 
electrochemical detection method in literature. This assay will be used to evaluate the 
extent of liver protection offered by systemic or regional administration of amifostine in 




Table 3.1. Interday variability of slopes and intercepts derived from the standard curves of amifostine in plasma (the peak height 
ratios of WR 2721 to WR 80855 over the range of WR 2721 concentration in human plasma of 0.5 to 40 μM are plotted against WR 
2721 concentration; lnC vs lnPHR) 
 
 
 0.5μM 1μM 5μM 10μM 20μM 40μM Slope Intercept R2 
Run 1 
(11/24/03) 
0.4836 1.006 5.5 11.03 20.91 38.125 1.1553 -1.4632 0.9987 
 0.4626 0.9989 5.206 10.41 18.684 36    
Run 2 
(11/25/03) 
0.475 1.005 5.223 10.36 20.51 36.34 1.1407 -1.386 0.9988 
 0.465 1.07 5.11 10.71 20.72 37.18    
Run 3 
(11/26/03) 
0.504 0.921 5.686 10.43 19.29 38.67 1.1113 -1.3109 0.9988 
 0.522 0.921 4.994 10.78 18.94 39.41    
N 6 6 6 6 6 6 3 3 3 
Mean 0.4854 0.9870 5.2865 10.62 19.8423 37.6208 1.1358 -1.3867 0.9988 
S.D. 0.0234 0.0573 0.2578 0.2644 0.9815 1.3430 0.0224 0.0762 0.0001 
%RSD 
(Precision) 
4.8168 5.8075 4.8773 2.4899 4.9466 3.5698    
%RE 
(Accuracy) 






Table 3.2. Interday variability of slopes and intercepts derived from the standard curves of WR1065 in human deproteinized whole 
blood (the peak height ratios of WR1065 to WR 251833 over the range of WR1065 concentration in human deproteinized whole 




0.148 μM 0.37 μM 0.74 μM 1.48 μM 3.7 μM 7.4 μM Slope Intercept R2 
Run 1 
(04/08/04) 
0.0868 0.145 0.32 0.694 1.393 3.789 8.222 1.0022 -0.7696 0.9961 
Run 2 
(04/09/04) 
0.0685 0.154 0.379 0.771 1.525 3.583 7.2 1.0459 -0.8948 0.9992 
Run 3 
(04/10/04) 
0.081 0.137 0.359 0.743 1.417 3.991 7.281 1.0417 -0.5538 0.9987 
N 3 3 3 3 3 3 3 3 3 3 
Mean 0.08 0.15 0.35 0.74 1.45 3.79 7.57 1.03 -0.739 0.998 
S.D. 0.01 0.01 0.03 0.04 0.07 0.2 0.57 0.024 0.172 0.002 
% RSD 
(Precision) 
11.87 5.85 8.51 5.30 4.87 5.39 7.51 2.341 -23.33 0.167 
% RE 
(Accuracy) 







Table 3.3. HPLC assay validation for WR1065 in human deproteinized whole blood 
 
 0.1 48 μM 1.48 μM  7.4 μM  
Run 1 (04/08/04) 0.1589 1.433 8.168 
 0.1561 1.467 8.496 
 0.1325 1.469 8.28 
Run 2 (04/09/04) 0.152 1.515 7.32 
 0.155 1.493 7.4 
 0.153 1.517 7.169 
Run 3 (04/10/04) 0.146 1.316 8.017 
 0.139 1.314 6.933 
 0.149 1.238 6.551 
N 9 9 9 
Mean 0.15 1.42 7.59 
S.D. 0.01 0.1 0.67 
%RSD (Precision) 5.76 7.21 8.85 
















Table 2.4. HPLC assay validation for WR 2721 in human plasma 
 
 1μM 10μM 40μM 
Run 1 (11/24/03) 0.938 10.86 36.33 
 0.961 10.655 35.32 
 0.938 10.655 36.42 
Run 2 (11/25/03) 0.9899 10.557 37.89 
 0.8738 10.41 36.15 
 1.031 11.75 36.95 
Run 3 (11/26/03) 0.8138 10.42 37.02 
 0.9914 9.795 37.81 
 0.9418 10.75 39.53 
N 9 9 9 
Mean 0.942 10.650 37.047 
S.D. 0.065 0.514 1.233 
%RSD (Precision) 6.934 4.827 3.328 

























               Blank human plasma                        0.5μM Amifostine + 1ug/ml IS in plasma            10μM Amifostine+ 1μg/ml IS in plasm 
 





           Blank human whole blood              0.15 μM WR1065 +0.5μg/ml IS in whole blood   1.5μM WR1065 + 0.5μg/ml IS in whole blood 
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RELATIONSHIP BETWEEN AMIFOSTINE DOSE, ADMINISTRATION 
ROUTE (SYSTEMIC VS REGIONAL), AND SAMPLING TIME ON WR-1065 
EXPOSURE IN THE LIVER OF TUMOR-BEARING RATS 
 
ABSTRACT 
The objective of the present study was to determine whether or not a higher liver to tumor 
ratio of the cyto- and radioprotective metabolite WR-1065 could be achieved following 
regional as opposed to systemic dosing of the inactive prodrug amifostine. Walker 256 
cells were injected directly into the liver of male rats and focal tumors were allowed to 
grow for 12-14 days. Amifostine was then administered by a 3-min infusion into either 
the portal vein (i.e., regional) or femoral vein (i.e., systemic).  The experiments were 
performed according to a central composite experimental design, with doses of 50, 125, 
275, 425 and 500 mg/m2 and post-treatment sampling times of 15, 21.5, 37.5, 53.5 and 60 
min. Liver, tumor and blood samples were analyzed for WR-1065 by HPLC with 
electrochemical detection.  Response surface regression models were fit to the log-
transformed concentrations from regional and systemic experiments. The concentrations 
of WR1065 in the liver, tumor, blood, and liver to tumor ratio were not statistically 
different after regional or systemic dosing of amifostine in tumor-bearing rats (p>0.05).  
However, during both routes of drug administration, liver to tumor ratios were highest at 
the largest dose (500 mg/m2, p<0.0001) and earliest sampling time (15 min, p<0.0001), 
achieving ratios of 4-5. Moreover, 2-D dose-response plots indicated that the kinetics of 
WR1065 were nonlinear. No significant differences were observed between regional and 
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systemic routes of administration for amifostine in tumor-bearing rats.  However, it 
appears that the therapeutic index (i.e., liver to tumor ratio) of WR1065 may be 
optimized by increasing the amifostine dose within safe limits and by delivering 






















                                                        INTRODUCTION 
 
Cytoprotectant Amifostine protects almost all normal tissues from the cytotoxic effects of 
radiation and some chemotherapeutic agents.[4,5] It is a thiophosphate prodrug that is 
dephosphorylated to the free thiol active metabolite, WR-1065, by the plasma membrane 
bound enzyme alkaline phosphatase and WR1065 is the form of the drug taken by the 
cell.[6] The high alkaline phosphatase activity was localized in the endothelium of small 
arteries and arterioles at their origin from larger vessels.[7] As to the liver, it contains 
relatively less alkaline phosphatase compared with tissues such as the small intestine or 
kidney. In the liver of humans, the strongest activity was found in the sinusoids and the 
endothelium of the central and periportal veins which are in the central and peripheral 
part of the lobule but no alkaline phosphatase activity was found within hepatocytes. 
However, the localization of alkaline phosphatase in the human differs from that in the 
rat. No alkaline phosphatase activity in the sinusoids and low activity in the bile 
canaliculi of the rat. Periportal activity predominates in the rat.[8]  A number of studies 
have attempted to characterize the mechanism of differential protection when amifostine 
is administered systemically. WR1065 may be actively absorbed by normal tissue cells 
and only passively absorbed by tumor cells. The polyamine transport system is probably 
responsible for the mediated uptake mechanism for WR1065 in the low micromolar 
concentration range and WR1065 is taken up by passive diffusion at high millimolar 
concentration level.[9,10] The selective uptake of WR-1065 may also be due to differences 
in the tissue microenvironment resulting in the slow entry of the free thiol into tumor 
masses. Tumors are often relatively hypovascular and have low interstitial pH, resulting 
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in low rates of prodrug activation by alkaline phosphatase. In addition, the distribution of 
alkaline phosphatase in capillaries and arterioles of normal tissues is extensive as 
compared with tumors. Thus, in tumors it is thought that both reduced metabolism of 
amifostine to the active protector WR-1065 and the low uptake of WR-1065 by the tumor 
result in a concentration of the free thiol that is much lower than that found in normal 
organs.[11,12] As a result, healthy tissue is protected from radiotherapy and chemotherapy 
while tumors with lower levels of the active metabolite are less protected. Transient 
hypotension, however, is the major dose-limiting adverse effect of amifostine. The main 
metabolic pathway of WR-1065 elimination involves the formation of symmetrical and 
nonsymmetrical disulfides that might serve as a depot for the active metabolite, free WR-
1065.[13,14] 
  Compared with intravenous administration, regional chemotherapy may deliver high 
concentrations of drug to a desired target site while reducing the systemic exposure of 
drug. Amifostine may be a good candidate for regional drug delivery to the liver because 
it has a large clearance from the body and is eliminated more extensively by the liver than 
by the gastrointestinal tract, lungs, or kidneys.[15-17] Approximately 90% of the drug is 
extracted by the liver (i.e., converted to WR-1065), suggesting that the liver may 
preferentially take up the active free thiol, WR-1065.[18] We hypothesized that organs 
with high amifostine clearance and extraction ratio would have a high activation rate of 
amifostine to WR-1065 and, therefore, would be protected by amifostine. 
Amifostine has shown in randomized trials to protect the kidney from cisplatin 
nephrotoxicity and the parotid gland from radiation due to the greater conversion of the 
drug to the active metabolite WR-1065 in the normal tissue than in the tumor. Protection 
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appears to result from scavenging oxygen-derived free radicals and hydrogen donation to 
repair damaged target molecules. Each of these mechanisms requires that the active 
metabolite be present at the time of radiation. WR-1065 may also affect the catalytic 
inactivation of topoisomerase II, which slows cell cycling, thus providing more time for 
DNA repair.[19] In order to optimize the use of amifostine as a radiation protector of 
normal liver, which will permit the safe delivery of higher doses of radiation for patients 
with both focal and diffuse disease, we performed preclinical studies to optimize 
selectivity and to estimate the appropriate dose of regional and/or systemic amifostine. 
Amifostine is administered in the clinic at a dose of 200 ~ 350 mg/m2 as IV bolus 
injection or 3-min infusion 15 ~ 30 min before the start of radiotherapy. In our preclinical 
study, the objective was to evaluate the potential advantage of amifostine regional 
administration to the liver and the relationship of selectivity (liver to tumor concentration 
ratio of WR1065) to the different doses and times after systemic and/or regional 
administration of amifostine. Thus, the concentrations of the active metabolite, WR-1065, 
were determined in the blood, liver and tumor of a tumor-bearing rat model at different 
times after both routes of administration under different doses. Rats received different 
doses of amifostine over an infusion period of 3 min either through the femoral vein 
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Materials and Methods 
4.1 Animals 
Male Sprague-Dawley rats weighting approximately 125-175g were obtained from 
Harlan Sprague Dawley, Inc. (Indianapolis, Indiana). They were housed in cages in a 
temperature-humidity controlled room with a 12 h light-dark cycle and fed with 5001 
Rodent Diet (PMI Nutrition International, Inc. Brentwood, Mo). All animal procedures 
and study protocols were approved by the University of Michigan Committee on the Use 
and Care of Animals. 
4.2 Tumor implantation 
The rats were anesthetized using a 60 mg/kg intraperitoneal injection of pentobarbital. A 
mid-line abdominal incision was made starting at the xiphoid process and the liver was 
exposed. Walker 256 cells were grown in suspension cultures with RPMI media 
supplemented with 10% fetal calf serum and prepared for injection by suspension in 
phosphate buffered saline 7.4(PBS). The left lateral lobe (LL) of the liver was injected 
with tumor cells (~ 40μl) and the peritoneum and abdominal wall were closed. Focal 
tumors were allowed to grow for 12-14 days. The average weight of the tumors at the 
time of dosing was 0.385 g ± 0.343. 
4.3 Experimental protocol 
Tumor-bearing rats were divided randomly into two equal groups, each receiving 
amifostine either through the portal vein (regional) or the femoral vein (systemic). The 
rats were anesthetized using a 60 mg/kg intraperitoneal injection of pentobarbital and the 
femoral vein or portal vein was cannulated. Blood was drawn and seen in the cannula 
before dosing of amifostine. Approximate 1 ml of saline was injected over 60sec into the 
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portal vein and/or femoral vein to examine for leakage and to hydrate the animals before 
dosing of amifostine. A solution of amifostine (ALZA Pharmaceuticals, Palo Alto, or 
CA/US Bioscience, West Conchohocken, PA) at a dose of 50, 125, 275, 425 and 500 
mg/m2 was prepared in normal saline and administered as a 3-minute infusion using a 
syringe pump (Harvard Apparatus, South Natick, MA) set at 0.4 ml/min. Blood was 
obtained by cardiac puncture, and liver tissue and tumor samples were collected at 15, 
21.5, 37.5, 53.5 and 60 min after initiating the drug infusion under different doses. The 
whole experiment consisted of two rotatable response surface designs centered at a dose 
of 275 mg/m2 and a sampling time of 37.5 min. For each of the two modes (regional vs 
systemic) of administration, three animals were tested at each design point. Figure 4.1 
displays this response surface design. Concentrations of WR1065 were assessed in blood, 
liver and tumor; the ratio of liver concentration to tumor concentration, the therapeutic          
index, was also evaluated.  
Figure 4.1.  Response surface design 
 






































4.4 Assay for WR-1065[20] 
Concentrations of free WR-1065 were measured in the blood and tissues of rats, as 
described briefly below and detailed information of analytical methodology can be found 
in chapter 3. 
4.4.1 Sample preparation. Liver and tumor samples were dissected, weighed and frozen 
rapidly by putting them in a liquid nitrogen bath for 1 min. The samples were stored at -
70°C for subsequent analysis. On the day of analysis, the samples were homogenized 
(1:5, w/v) in an ice-cold deproteinizing solution containing 1.0M perchloric acid and 2.7 
mM (1g/L) disodium EDTA. The homogenate was then centrifuged at 40,000g for 5min 
(at 0°C) and WR-251833 was added as an internal standard into the supernatant. Blood 
samples were placed in tubes, containing ice-cold 1.0M perchloric acid and 2.7mM 
EDTA in a ratio of 1:1 (v/v), immediately after sampling. The mixture was then vortexed 
vigorously and centrifuged at 20,000g for 5min (at 0°C). The supernatant was stored at -
70°C for subsequent analysis. On the day of analysis, the samples were thawed, WR-
251833 was added as an internal standard, and a 20 μl aliquot was injected into the HPLC 
column. Using the described method, the limit of quantification was 0.25 μM. The linear 
range is 0.25 - 10 μM.  The method was validated by measuring samples that were spiked 
with known concentrations of WR-1065 (0.5, 2.5 and 10μM) on three different days. The 
interday variability (precision) of WR-1065 was less than 10% and the accuracy (bias) 
was less than 2%. 
4.4.2 HPLC analysis[22]. Analysis was performed on a Waters (Milford, Massachusetts) 
515 isocratic HPLC pump. WR-1065 and the internal standard WR-251833 were detected 
by a BAS (West Lafayette, Indiana) LC-4C amperometric detector equipped with a thin 
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film mercury-gold amalgam working electrode. The Hg/Au electrode potential was set at 
+0.15V with respect to the Ag/AgCl reference electrode and the range of the detector was 
set at 0.1μAFS. The column, 4.6×250mm, 5μm particle size, C18 Symmetry® Waters 
(Milford, Massachusetts), was operated at room temperature. The WR-1065 
chromatography protocol employed a mobile phase containing 0.1M chloroacetic acid 
sodium salt, 1mM sodium octyl sulfate, pH 3.0, and 30% (v/v) methanol running at 
1ml/min. Peak indentification was confirmed by comparing retention times in samples 
with authentic standards. Quantification was based on the peak height ratio of the 
compound and the internal standard. 
4.5 Statistics 
All analyses were performed using SAS v9.1.  The four endpoints (blood, liver, tumor, 
liver/tumor) were analyzed separately.  Write yijkl as any endpoint, measured on the lth 
animal of the ith set (denoting regional [1] or systemic [2] infusion) at dose dj and time tk. 
Per the original experimental design, the response surface regression model was initially 
fit to all the data using SAS PROC RSREG or SAS PROC GLM: 
E (yijkl) = βi0 + βi1 dj+ βi2 tk + βi3 djtk + βi4 dj2+ βi5 tk2 
The expected value, E (yijkl), was plotted against dose and time.  The null hypothesis of 
no difference between regional and systemic infusions is realized as:   
Ho: β10=β20, β11=β21, β12=β22, β13=β23, β14=β24, β15=β25,  
and can be tested using the CONTRAST statement in SAS PROC GLM. In a second 
analysis, the logarithmic transform was applied to the endpoints, and the analysis 
repeated with a reduced model: 




which was found to have a better fit than the original model. Issues with these models are 
explored in the Discussion. 
Results 
WR-1065 in liver The response surface of WR-1065 concentration in liver, after regional 
or systemic dosing of amifostine, is shown in Figure 4.2, where the tendency of both 
response surfaces to go up from the point with low dose and long sampling time to the 
point with high dose and short sampling time is observed. The maximal concentration in 
the liver was achieved with 500 mg/m2 at 15min, regardless of the route of 
administration. The maximal concentration of WR-1065 in liver was 400 μM for femoral 
vein infusion and 275 μM for portal vein infusion. The F test indicates the difference 
between the two routes is statistically significant (p = 0.02). However, the response 
surfaces do not achieve a maximum within the experimental range. If we study the plots 
of concentration of WR-1065 in liver versus dose under different sampling time with two 
different dosing routes, which are shown in Figure 4.3, we see a very similar pattern of 
curves instead of straight lines in these two plots for femoral and portal vein infusion. 
The WR-1065 concentration in liver increases with dose, where the rate of increase 
depends upon the sampling time; the shorter the sampling time, the higher the WR-1065 
concentration in liver and the steeper the curve. The WR1065 concentration in liver is 
dose dependent, which is shown by a disproportional increase in concentration with 
increased dose. The WR-1065 concentrations in liver versus time under different doses 
after regional or systemic dosing of amifostine are shown in Figure 4.4. As seen in this 
figure, the WR-1065 concentration in liver goes down as the sampling time increases and 
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the dose decreases. The earlier the sampling time, the higher the concentration of WR-
1065 in the liver.  
WR-1065 in tumor Response surface of the WR-1065 concentration in tumor is shown 
in Figure 4.5. That the maximal concentration in tumor is much lower than that obtained 
in liver tissue is demonstrated. However, there is no statistical difference between 
femoral and portal route regarding of the concentration of WR-1065 in tumor (F test; p = 
0.23) within our experimental dose range. Dose-dependent feature can also be observed 
in the plot of the concentration of WR-1065 in the tumor versus dose (Figure 4.6), and 
the concentration of WR1065 in tumor increase with dose. In Figure 4.7, the 
concentration of WR1065 in tumor decrease with the time, however, its concentration 
increase with the time relative to the liver. 
WR1065 liver to tumor ratio The response surface of WR-1065 concentration ratios for 
liver to tumor was shown in Figure 4.8. As shown in this figure, the maximal ratio is 
around 4~5 with both routes of administration, suggesting amifostine can selectively 
protect the normal tissue over tumor.  Likewise, there is no statistical difference between 
these two administration routes regarding of the ratio of the concentration of WR-1065 in 
liver to tumor (F test; p=0.96) within this experimental range. In Figure 4.9, the 
concentration ratios of WR1065 in liver to tumor is increasing with the dose nonlinearly. 
And this ratio decrease with the time in Figure 4.10. Its highest value achieved at high 
dose and short time. 
WR1065 in blood The response surface of the concentration of WR1065 in blood is 
shown in Figure 4.11. The F test (p=0.87) suggests there is no statistical difference 
between these two routes regarding of the concentration of WR-1065 in blood. We also 
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observed similar patterns with the concentration of WR1065 in blood with dose and time 




Figure 4.2. Response surface of WR1065 concentrations in liver 
 
 85 
          
 
Figure 4.3. Liver concentrations of WR1065 as a function of dose for given sampling times 
 
 




                  






















Figure 4.10. Liver/tumor concentration ratios of WR1065 as a function of sampling time for 
given doses  
      
Figure 4.11. Response surface of WR1065 concentrations in blood 
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Figure 4.12. Blood concentrations of WR1065 as a function of dose for given sampling time 
 




Amifostine is administered at a dose of 200~350 mg/m2 in the clinic as a 3-min infusion 
or IV bolus injection 15 -30 min before the start of radiotherapy. Based on this clinic 
setting during radiotherapy, we studied a dose range of 50 ~ 500 mg/m2 with a sampling 
time up to one hour. We expected the optimum condition, i.e., the maximal value of the 
ratio of the concentration of WR-1065 in liver to tumor to be within this experimental 
range. We designed a second-order experiment which is shown in the Experimental 
protocol for this experimental range and originally proposed the second-order model, 
E(yijkl) = βi0 + βi1dj + βi2tk + βi3tkdj + βi4dj2 + βi5tk2, to approximate the true response 
surface, because, if the maximum was obtained in the experimental range, it could be 
easily identified from the model. However, residual analysis (not shown) demonstrated 
significant lack of fit, and several of the response surface models displayed saddle points, 
rather than maxima. We achieved better fits to both regional and systemic data by 
logarithmically transforming the WR1065 concentrations, and determined that quadratic 
terms in dose and time destabilized the parameter estimation. This led us to our final 
model. The increased dose caused a disproportional increase of concentration, 
implicating non-linear pharmacokinetics of WR1065 and possible saturation of an 
elimination pathway(s) and/or uptake/retention in tumor, relative to liver. Higher ratios of 
WR1065 in liver to tumor can apparently be achieved at earlier sampling times regardless 
of administration route. This means we need to start radiation therapy as soon as possible 
after dosing of amifostine as long as no systemic toxicity. If we compare the 
concentration of WR1065 between liver and tumor at different time points, we can see 
that WR1065 concentrations in tumor exceed that in liver at later sampling points. This 
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supports above the conclusion that radiation is not acceptable at later times.  Another aim 
of this experiment is to test if regional delivery of amifostine to the liver through the 
portal vein can generate higher concentration ratios of WR1065 in liver to tumor than that 
obtained by systemic delivery of amifostine through the femoral vein. Based on the test 
of equality of two models fitted by the data from portal and femoral vein infusion, 
respectively, we did not see a statistical difference between these two routes regarding of 
the ratio of WR1065 concentration in liver to tumor. Actually, we have had some 
preliminary preclinical results[23] which indicated that portal vein administration of 
amifostine increased WR1065 selectivity to the liver compared with systemic 
administration. This was demonstrated by the reduction of WR1065 tumor concentrations 
following regional dosing to as much as one-fifth the concentrations achieved following 
intravenous infusion. In that study, amifostine was administered at a dose of 200mg/kg as 
a 15min infusion to tumor-bearing rats either by femoral vein (systemic) or portal vein 
(regional) and tissue and blood samples were collected at 15, 20, 30, 45 and 60min after 
initiating the drug infusion. We observed the statistical difference between these two 
routes as to the WR1065 liver/tumor ratios at 30 and 45min sampling times. However, 
p.v. infusions of amifostine increased substantially the systemic exposure to WR1065, 
compared with i.v. infusion of the same dose. With the same schedule of amifostine: a 
15-min infusion at 200mg/kg, we also evaluated whether systemic or portal venous 
administration of amifostine could protect the normal liver from the effects of ionizing 
radiation without compromising tumor cell kill in a same rat liver tumor model[17]. Both 
amifostine conditions (systemic vs regional) showed considerably less radiation effect 
than saline-treated controls; the two amifostine conditions did not differ. Based on these 
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previous results, we proposed to further investigate the significance of regional route over 
systemic administration and optimum condition of dose and timings in a more systematic 
fashion. We tried to optimized the schedule of amifostine with the dose and timings and 
compare the systemic and regional route of administration in this response surface 
experiment. Contrasted to our previous conclusions, we didn’t see a statistical difference 
between these two routes, probably because previously, investigation was done with the 
single dose level which results in the limitation of the studies. In our current studies, the 
response surface was generated within a specific experimental range and the conclusion 
of no difference between regional and systemic dosing was made based on this more 
systematic study. For the benefit of clinical treatment, WR1065 concentration ratios for 
liver to tumor increase with the dose increase and this selectivity increase with the 
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RELATIONSHIP BETWEEN AMIFOSTINE DOSE, ADMINISTRATION 
ROUTE (INTRAVENOUS VS SUBCUTANEOUS), AND SAMPLING TIME ON 
WR-1065 EXPOSURE IN THE LIVER OF TUMOR-BEARING RATS 
 
ABSTRACT 
The objective of the present study was to determine if a higher liver-to-tumor ratio of the 
cytoprotective metabolite WR-1065 could be achieved following intravenous as opposed 
to subcutaneous dosing of the inactive prodrug amifostine. Amifostine was administered 
either by subcutaneous or intravenous route into rats bearing liver tumors.  The 
experiment employed a central composite design, with doses of 100-1000 mg/m2 and 
post-treatment sampling times of 5-60 min. Liver, tumor and blood samples were 
analyzed for WR-1065 by HPLC with electrochemical detection.   Liver-to-tumor ratios 
were highest at the larger doses (550-1000 mg/m2) and earliest sampling time (5 min), 
achieving ratios of 6-8 after intravenous dosing. Liver and blood concentrations of WR-
1065 were highest at the first sampling time and decreased steadily over time, although 
tumor levels were relatively constant with respect to time. Following subcutaneous 
dosing of amifostine, the highest ratios (i.e., 4-6) were achieved at the higher doses (550-
1000 mg/m2) and sustained until 20 min post-dosing. Liver and tumor concentrations of 
WR-1065 were initially low, but increased over time, reaching a plateau for liver at 40-60 
min, and continuing to rise for tumor. Blood levels were relatively constant over time. 
These results suggest that the therapeutic selectivity (i.e., liver to tumor ratio) of WR1065 
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may be optimized by increasing the amifostine dose within safe limits and by delivering 
radiotherapy ≤15 min after IV administration. The subcutaneous route may be a 

























   
Amifostine protects almost all normal tissues from the cytotoxic effects of radiation and 
some chemotherapeutic agents [1,6].  It is a thiophosphate prodrug that is dephosphorylated 
to the free thiol active metabolite, WR-1065; by the plasma membrane bound enzyme 
alkaline phosphates [4].  Amifostine may be actively absorbed by normal tissue cells and 
only passively absorbed by tumor cells [3].  The selective uptake of WR-1065 and/or 
amifostine may also be due to differences in the tissue microenvironment resulting in the 
slow entry of the free thiol into tumor masses. Tumors are often relatively hypovascular 
and have low interstitial pH, resulting in low rates of prodrug activation by alkaline 
phosphates. In addition, the distribution of alkaline phosphates in capillaries and 
arterioles of normal tissues is extensive as compared with tumors. Thus, in tumors it is 
thought that both reduced metabolism of amifostine to the active protector WR-1065 and 
the low uptake of WR-1065 and/or amifostine by the tumor result in a concentration of 
the free thiol that is much lower than that found in normal organs [2,5].  As a result, 
healthy tissue is protected from radiotherapy and chemotherapy while tumors with lower 
levels of the active metabolite are less protected. The main metabolic pathway of WR-
1065 elimination involves the formation of symmetrical and nonsymmetrical disulfides 
that might serve as a depot for the active metabolite, free WR-1065 [10]. 
  Radiation therapy has played a minor role in the conventional management of patients 
with intrahepatic malignancies because the dose of radiation that can be delivered is 
limited by normal tissue toxicity referred to as radiation-induced liver disease (RILD). 
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For patients with focal intrahepatic cancers, three-dimensional treatment planning has 
permitted the delivery of high doses of radiation, leading to improved local control and, 
possibly, survival. However, many patients have disease that is too diffuse to be treated 
with focal techniques. Amifostine has been shown in randomized trials to protect the 
kidney from cisplatin nephrotoxicity and the parotid gland from radiation due to the 
greater conversion of the drug to the active metabolite WR-1065 in the normal tissue than 
in the tumor. Protection appears to result from scavenging oxygen-derived free radicals 
and hydrogen donation to repair damaged target molecules. WR-1065 may also affect the 
catalytic inactivation of topoisomerase II, which slows cell cycling, thus providing more 
time for DNA repair [8].  In order to optimize the use of amifostine as a radiation protector 
of normal liver, which will permit the safe delivery of higher doses of radiation for 
patients with both focal and diffuse disease, we performed nonclinical study to optimize 
selectivity and to estimate the appropriate dose of intravenous and/or subcutaneous 
amifostine. 
The IV administration of 200 to 350 mg/m2 amifostine 15-30 minutes before each 
radiotherapy fraction is the usual recommended schedule for radioprotection. However, 
IV administration requires the availability of a day clinic attached to the radiotherapy 
unit, and a specialized nurse to treat the potential side effects related to amifostine 
infusion, such as acute hypotension and severe nausea and vomiting. Moreover, it can be 
difficult to administer the drug, transport the patient and initiate RT within the approved 
15-to-30-minute time frame. Clearly, a simpler but equally effective mode of 
administration would make amifostine more convenient for both the patient and the 
practitioner. Subcutaneous administration of amifostine could potentially reduce the side 
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effects of the drug and be significantly more convenient for both patients and radiation 
oncologists. Amifostine is not currently approved for SC administration in the United 
States. However, evaluation of administration via this route is ongoing in the settings of 
chemotherapy and fractionated radiation therapy. To be clinically useful, the SC route 
would have to be as effective as IV administration. 
In our nonclinical study, the objective was to evaluate the potential advantage of 
amifostine subcutaneous administration to the liver and the relationship of selectivity 
(liver to tumor concentration ratio of WR1065) to the different doses and times after 
intravenous and/or subcutaneous administration of amifostine. Thus, the concentrations 
of the active metabolite, WR-1065, were determined in the blood, liver and tumor of a 
tumor-bearing rat model at different times after both routes of administration under 















Material and Methods 
 
5.1 Chemicals 
Amifostine and WR1065 standards were generously provided by the division of 
experimental therapeutics, department of chemical information, Walter Reed Army 
Institute of Research (Silver Spring, Maryland). Amifostine (bulk) was provided by 
ALZA Pharmaceuticals (Palo Alto, CA). Perchloric acid 70% (redistilled) was obtained 
from Aldrich Company (Milwaukee, WI). EDTA disodium salt was purchased from the 
Sigma Chemical Company (St. Louis, MO). HPLC grade methanol, water, phosphoric 
acid were purchased from Fisher Scientific (Pittsburgh, PA).  
5.2 Animals 
Male Sprague-Dawley rats weighting approximately 125-175g were obtained from 
Harlan Sprague Dawley, Inc. (Indianapolis, Indiana). They were maintained in a 
temperature-humidity controlled room on a 12 h light-dark cycle with access to 5001 
Rodent Diet (PMI Nutrition International, Inc. Brentwood, Mo) and water. All animal 
procedures and study protocols were approved by the University of Michigan Committee 
on the Use and Care of Animals. 
5.3 Tumor implantation 
Rats were anesthetized using a 60 mg/kg intraperitoneal injection of pentobarbital. A 
mid-line abdominal incision was made starting at the xiphoid process and the liver was 
exposed. Walker 256 adenosarcoma cells were grown in suspension cultures with RPMI 
media supplemented with 10% fetal calf serum and prepared for injection by suspension 
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in phosphate buffered saline 7.4(PBS). The left lateral lobe (LL) of the liver was injected 
with tumor cells (~ 30μl) and the peritoneum and abdominal wall were closed for 
recovery. Tumors were allowed to grow for ~14 days.  
5.4 Experimental protocol 
Tumor-bearing rats were divided randomly into two equal groups and were anesthetized 
using a 60 mg/kg intraperitoneal injection of pentobarbital. For intravenous 
administration, femoral vein was cannulated and blood was drawn and seen in the 
cannula before dosing of amifostine. Approximate 1 ml of saline was injected over 60 sec 
into femoral vein to examine for leakage and to hydrate the animals before dosing of 
amifostine. For subcutaneous administration, Amifostine is injected into the center of the 
‘tent’ made by pinching the skin over the back of the rats. A solution of amifostine at a 
dose of 100, 232, 550, 868 and 1000 mg/m2 was prepared in normal saline and injected as 
a bolus dose either through subcutaneous administration or intravenous administration 
(femoral vein). Blood was obtained by cardiac puncture, and liver tissue and tumor 
samples were collected at 5, 13.05, 32.5, 51.95 and 60 min after initiating the drug 
administration under different doses. The whole experiment was designed with the 
method of central composite design centered at a dose of 550 mg/m2 and a sampling time 
of 32.5 min. The levels and design are given in Table 5.1 and Table 5.2.  For each of the 
two modes (IV vs SC) of administration, at least three animals were tested at each design 
point. Concentrations of WR1065 were assessed in blood, liver and tumor; the ratio of 
liver concentration to tumor concentration, the therapeutic selectivity, was also evaluated.  
5.5 Determination of WR-1065[7] 
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Liver and tumor tissue samples were dissected, weighed and were homogenized (1:5, 
w/v) in an ice-cold deproteinizing solution containing 1.0M perchloric acid and 2.7 mM 
(1 g/L) disodium EDTA; blood samples were placed in tubes, containing same 
deproteinizing solution in a ratio of 1:1 (v/v), immediately after sampling. All mixture 
was then centrifuged at 20,000g for 5min (at 4°C) and the supernatant were stored at -
70°C for subsequent analysis. On the day of analysis, WR-251833 was added as an 
internal standard into the supernatant and a 20 μl aliquot was injected into Waters 
(Milford, Massachusetts) Symmetry® C18 column (4.6×250mm, 5μm). Assay was 
performed with a Waters 515 isocratic HPLC pump coupled with a BAS (West Lafayette, 
Indiana) LC-4C amperometric detector equipped with a thin film amalgamated working 
electrode. The Hg/Au electrode potential was set at +0.15V with respect to the Ag/AgCl 
reference electrode and the range of the detector was set at 0.1μAFS. Mobile phase was 
0.1M chloroacetic acid sodium salt and 1mM sodium octyl sulfate, pH 3.0, mixed with 
30% (v/v) methanol. The flow rate was 1ml/min. The limit of quantification of this 
analytical method was 0.25 μM with the linear range of 0.25 - 10 μM. Quantification was 
based on the peak height ratio of the compound and the internal standard. 
5.6 Data Analysis 
All analyses were performed using SAS v9.1.  The four endpoints (concentration of 
WR1065 in blood, liver, tumor and concentration ratio of WR1065 in liver to tumor) 
applied with logarithmic transform were analyzed separately.  Write yijkl as any endpoint, 
measured on the lth animal of the ith set (denoting IV [1] or SC [2] injection) at dose dj 
and time tk. The final model of different endpoints was determined by stepwise selection 
from initial response surface regression model, E (log (yijkl)) = βi0 + βi1 dj+ βi2 tk + 
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βi3 djtk + βi4 dj2+ βi5 tk2, using SAS PROC REG. The null hypothesis of no difference 
between IV and SC injection is realized as:  Ho:  β10=β20, β11=β21, β12=β22, β13=β23, 
























                                                                   Results 
WR-1065 in liver  
WR-1065 concentrations in liver versus time profiles under different doses (100-1000 
mg/m2) after intravenous or subcutaneous dosing of amifostine are shown in Figure 5.1. 
As seen in this figure, following intravenous dosing of amifostine, WR-1065 
concentration in liver was highest at the earliest sampling time (5 min) and decreased 
steadily over time for all doses; the concentration of WR1065 in liver was directly 
proportional to doses. Amifostine doses of 868 mg/m2 and 1000 mg/m2 did not produce 
significantly different WR-1065 concentrations in liver indicated by the confidence 
intervals. Following subcutaneous dosing of amifostine, the concentration of WR1065 in 
the liver was initially very low and increased over time, reaching a plateau at 40-60 min 
for all doses. As with intravenous dosing, liver concentrations of WR-1065 after 
subcutaneous administration was directly proportional to the dose and did not 
significantly differ between amifostine doses of 868 and 1000 mg/m2. Statistical test (F 
test) indicated there is a significant difference between the routes of intravenous and 
subcutaneous administration regarding the concentration of WR1065 in liver (P < 0.05). 
When we plot concentration of WR-1065 in liver versus blood concentration of WR1065 
for two different routes in Fig 5.5 (A), we observe a good correlation between liver 
concentration and blood concentration for both routes, and regression lines for two 
different routes indicate they are similar regarding this correlation. The higher the blood 
concentration is, the higher the liver concentration is.  
WR-1065 in tumor  
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The concentrations of WR-1065 concentrations in tumor over time by dose after 
intravenous or subcutaneous dosing are shown in Figure 5.2. Following the intravenous 
administration of amifostine, the WR-1065 concentration in tumor was relatively 
constant with respect to time, but increased with doses. Following subcutaneous dosing 
of amifostine, concentration of WR1065 in tumor was initially low, but continued to 
increase over time. Statistical test (F test) indicated there is a significant difference 
between the routes of intravenous and subcutaneous administration regarding the 
concentration of WR1065 in tumor (P < 0.05). In Fig 5.5 (B), we still observe a 
correlation between tumor concentration and blood concentration of WR-1065. 
WR1065 liver to tumor ratio  
Because Amifostine is a cytoprotective agent, higher concentration of WR1065 in liver 
compared to tumor which results in the higher selectivity which is the ratio of WR-1065 
in liver to tumor is expected. The ratio of WR1065 concentrations in liver to tumor versus 
time after intravenous or subcutaneous dosing of amifostine are shown in Figure 5.3. 
Following intravenous dosing of amifostine, the ratio increased with dose, and was 
highest at the earliest sampling time (5 min), decreasing steadily over time for all doses. 
To achieve higher ratio of WR1065, there is no observable significant difference within 
the range of doses of 550-1000 mg/m2. Following subcutaneous dosing of amifostine, the 
ratio was also highest at the earliest sampling time (5 min) and sustained till 15 min, then 
decreased steadily with respect to time; the ratio is proportional to doses. There was no 
significant difference in the range of 550 and 1000 mg/m2 for achieving higher ratio. 
Here is a significant difference between the routes of intravenous and subcutaneous 
administration regarding the ratio of WR1065 in liver to tumor (P < 0.05). We expect 
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higer liver-to-tumor ratio, but not very high blood concentration of WR-1065 which 
could result in the toxicity. Fig 5.5 (C) clearly indicate IV administration can achieve 
higher liver-to-tumor ratio compared to SC administration with relatively higer liver 
concentration than SC administration, there is a better correlation for IV administration 
between ration and liver concentration than SC administration. Highest ratio with SC 
administration doesn’t mean we have higher liver concentration at the same time, partial 
because of much lower concentration of WR-1065 in tumor.  
WR1065 in blood  
The WR-1065 concentrations in blood versus time under different doses (100-1000 
mg/m2) after intravenous or subcutaneous dosing of amifostine are shown in Figure 5.4. 
Following intravenous dosing of amifostine, the WR-1065 concentration in blood was 
highest at the earliest sampling time (5 min) and decreased steadily over time for all 
levels of doses; the higher concentration of WR1065 in blood was generated with the 
higher dose in this study (550-1000 mg/m2) and the concentration was low at the low 
levels of doses (100-232 mg/m2). There is no significant difference observed in achieving 
high concentration of WR1065 in blood between 868 and 1000 mg/m2.  Following 
subcutaneous dosing of amifostine, blood levels were relatively constant within the range 
of time (5-60 min) in this study; the highest blood level was generated with the highest 
dose of 1000 mg/m2 and the level of concentration of WR1065 in blood goes down as the 
dose decreases. To achieve higher concentration of WR1065 in blood with the route of 
subcutaneous administration, first two higher levels of doses, 868 and 1000 mg/m2 didn’t 
differ significantly.  Statistical test (F test) indicated there is a significant difference 
between the routes of intravenous and subcutaneous administration regarding the 
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concentration of WR1065 in blood (P < 0.05). IV administration can result in higher ratio 
with higher blood concentration compared to SC administration in Fig 5.5 (D), but the 
big advantage of high ratio with IV administration will also be dependent on the 






















                                                                 Discussion 
Amifostine is administered at a dose of 200~350 mg/m2 in the clinic as a 3-min IV 
infusion or bolus injection 15-30 min before the start of radiotherapy. Compared to IV 
administration, SC route presents some advantages over IV route when amifostine is used 
during fractionated radiotherapy because of its simplicity and reduced toxicities. Based 
on above clinic setting during radiotherapy, we studied a dose range of 100-1000 mg/m2 
with a sampling time up to one hour to explore the SC administration as an alternative 
route systemically. We expected the optimum condition, i.e., the maximal value of the 
ratio of the concentration of WR-1065 in liver to tumor to be within this experimental 
range.  
We consider three factors which are dose, time and route to affect responses which are 
concentration of WR1065 in tissue and blood in this study. We designed a second-order 
response surface study which is shown in the Experimental protocol for this experimental 
range based on factorial experiments instead of one-factor-at-a-time approach and 
originally proposed the second-order linear model, E (yijkl) = βi0 + βi1dj + βi2tk + βi3tkdj + 
βi4dj2 + βi5tk2, to approximate the true response surface, because, if the maximum was 
obtained in the experimental range, it could be easily identified from the model. By 
comparison with the one-factor-at-a-time approach, factorial design method requires less 
runs for the same precision in effect estimation and conclusion from this analysis can be 
more general. Comparison between IV and SC administration can be indicated by the test 
of coincidence of response surfaces which was generated in this study. However, residual 
analysis (not shown) demonstrated some lacks of fit, and several of the response surface 
models displayed saddle points, rather than maxima. We achieved better fits to both IV 
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and SC data by logarithmically transforming the WR1065 concentrations, and determined 
statistically significant independent variables to enter the model for different dependent 
variables in this study by stepwise model-selection method at the level of entry and stay 
both equals 0.05. And it also seems that regression model weighted by the inverse of the 
sample variances within replicates can produce better fit than ordinary least square. All of 
above investigations led us to our final model for each dependent variable in our study. 
Among our four response variables, we consider higher ratio of WR1065 concentration in 
liver to tumor with high enough concentration of WR1065 in liver as a good indicator of 
protection.  
For the route of intravenous administration, higher ratios of WR1065 in liver to tumor 
can apparently be achieved at earlier sampling times. This means we need to start 
radiation therapy as soon as possible after dosing of amifostine as long as no systemic 
toxicity which is indicated by the concentration of WR1065 in blood. Because there is no 
observable difference among first three levels of doses (550, 868, 1000mg/m2) in 
achieving high ratio and lower doses produce lower blood concentration of WR1065, we 
are more interested in the range of 550-868 mg/m2 to generate good protection with 
acceptable toxicity.  If we compare the concentration of WR1065 between liver and 
tumor at different time points, we can see that WR1065 concentrations in tumor were 
relatively constant over time, which results in the ratio is very dependent on the 
concentration of WR1065 in liver which is lower at later sampling points. This supports 
above conclusions that radiation is not acceptable at later times.  
For the route of subcutaneous administration, blood levels were relatively constant over 
time and significantly lower than those from IV administration indicating less toxicity 
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with SC administration compared with IV administration. Higher ratio was also generated 
at earlier sampling time with SC administration and can be sustained for a period of time 
which can provide flexible time frame to start radiotherapy clinically. The mechanism of 
producing higher ratio at earlier time can be clear by studying the concentration profile of 
WR1065 in liver and tumor after SC administration. Initially, at the earlier sampling time, 
both WR1065 concentration in liver and tumor are low compared with later sampling 
times and concentration of WR1065 in liver is much higher than that in tumor. 
Concentration of WR1065 in tumor continue to increase with respect to time, but 
concentration of WR1065 in liver reached a plateau around 40-60 min. All of these 
results indicate that there will be no benefit if the radiotherapy start during the later time 
typically after 30 min, and probably the concentration of WR1065 in liver is low if we 
start radiotherapy during earlier time.  
Based on our criterion of effectiveness of protection, IV administration is better than SC 
administration because the ratio generated by IV administration is higher than that from 
SC administration (6-8 vs. 4-6) at earlier sampling time and we can have high 
concentration of WR1065 in liver with IV administration during the time when the higher 
ratio can be observed.   Another aim of this experiment is to test if SC administration of 
amifostine can be equivalent in generating concentration of WR1065 in liver, tumor, 
blood and concentration ratio of WR1065 in liver to tumor to that obtained by systemic 
delivery of amifostine through the femoral vein. Based on the test of equality of two 
models fitted by the data, we found a statistical difference between these two routes 
regarding all of above responses (P<0.05). The result indicated there exists significant 
difference between subcutaneous and intravenous routes of administration for amifostine 
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probably because there should be an absorption process of drug for subcutaneous 
administration.  Because all maximum responses can be achieved at early time and higher 
dose with intravenous administration, with as low as possible blood level, 550mg/m2 can 
still achieve ratio of 7~8 with much higher WR1065 concentration in liver than that with 
subcutaneous route with same dose (550 mg/m2). In our current studies, the response 
surface was generated within a specific experimental range and the conclusion of 
difference between IV and SC dosing was made based on this more systematic study. For 
the benefit of clinical treatment, WR1065 concentration ratios for liver to tumor increase 
with the dose increase and this selectivity increase with the sampling time decrease are 
our main finding with IV administration from this study, the subcutaneous route offers a 
less complicated method of administering amifostine to patients and may be a reasonable 
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Coded and uncoded levels Factor 
-1.414         -1           0           1            1.414 
A. Dose (mg/m2) 
B. Time (min) 
C. Route 
 100           232        550       868          1000 
   5           13.05      32.5     51.95           60 




TABLE 5.2. Design matrix for central composite design 















































































Fig.  5.1.  Concentration-time profile of WR1065 in liver of tumor-bearing rats by doses 
 





 Fig.  5.3. Ratio-time profile of WR1065 in liver to tumor by doses 
 
Fig.  5.4. Concentration-time profile of WR1065 in blood of tumor-bearing rats by doses 
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Fig.  5.5. Scatter plot of concentration of WR-1065 in (A) liver vs blood; (B) tumor vs 
blood; (C) liver-to-tumor ratio vs blood; (D) liver-to-tumor ratio vs liver, the number in 
parenthesis represent the dose and time on each point, the vertical and horizontal line on 
each point (mean value) represent the SEM of dependent and independent variables, 




PHARMACOKINETICS OF AMIFOSTINE AND ITS METABOLITE WR-1065 






To investigate the pharmacokinetics of amifostine and its active metabolite WR1065 in 
liver cancer patients undergoing hepatic radiation, five patients received 340 mg/m2 of 
amifostine by intravenous bolus injection, 15 min prior to delivery of fractional radiation.  
Serial blood samples were collected predose, at 1, 3, 5, 15, 30, 45 and 60 min, and at 2, 3, 
4, 5 and 6 hr after dosing in patients on the first day of radiotherapy.  High-performance 
liquid chromatography with electrochemical detection was used for the analysis of 
amifostine and WR1065 in plasma and blood samples, respectively, from this clinical 
study.  The pharmacokinetics of amifostine and WR-1065 were analyzed simultaneously 
using the nonlinear mixed effect model NONMEM. One-compartment and two-
compartment models were compared and the best model was selected based on the 
overall goodness-of-fit, structural model and residual model.  The clearance of amifostine 
was 66.0 mL/min/kg, the volume of distribution was 0.31 L/kg and the half-life was 2.0 
min.  The clearance of WR1065 was 91.0 mL/min/kg, the central and peripheral volumes 
of distribution were 0.80 L/kg and 1.4 L/kg, respectively, and the terminal half-life was 
75.6 min.  The reliability of parameter estimation was acceptable and the interindividual 
variability was low. Amifostine has a short half-life, small volume of distribution and 
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large clearance indicating a rapid conversion to WR1065.  The active metabolite WR-
1065 has a longer half-life than the parent drug, and a larger volume of distribution, 
indicating extensive binding to tissues in the body.  The large clearance of WR1065 
























Amifostine [Ethyol, WR2721] is an experimental drug that provides significant 
radioprotection to many normal tissues but provides little or no protection to many 
experimental tumors.[1-5] This selectivity is thought to be based on the preferential 
formation and uptake of the active metabolite WR-1065 in normal tissues, as the result of 
higher amount and activity of alkaline phosphatase, the enzyme which converts 
amifostine to the active metabolite WR-1065 and a higher pH condition compared to 
tumor tissues.[6-9] Amifostine has been shown in randomized trials to protect the kidney 
from cisplatin nephrotoxicity and the parotid gland from radiation due to the greater 
conversion of the drug to the active metabolite WR-1065 in the normal tissue than in the 
tumor. The liver appears to be a particularly promising organ for a radioprotective 
strategy using amifostine because the dose of radiation that can be delivered to patients 
with intrahepatic cancer is limited by normal tissue toxicity referred to as radiation-
induced liver disease (RILD).[10] Based on described situation, even a modest increase in 
the dose of radiation that can be tolerated by the whole liver could benefit tens of 
thousands of patients a year. We hypothesize that the outcome of treatment can be 
improved further by the application of a radiation protector and we feel that the most 
promising radioprotector for the liver, based on both laboratory and clinical evidence, is 
the thiophosphate ester prodrug amifostine. To optimize the use of amifostine as a 
radiation protector of normal liver, we conducted a phase I trial of dose escalating 
radiation therapy with systemic amifostine for patients with focal and/or diffuse 
intrahepatic cancer. Our preclinical data demonstrate that, in fact, systemic administration 
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of amifostine produces more WR-1065 in the normal liver than in intrahepatic tumor, and 
this leads to radioprotection of the liver. For a better understanding of the mechanism of 
action and the metabolism of amifostine, pharmacokinetic studies of amifostine itself as 
well as its main metabolite WR-1065 may be of great importance. In this study, in order 
to obtain pharmacokinetic data for this dose, route, and schedule of amifostine and its 
metabolite in patients undergoing hepatic radiation, patients will receive 340 mg/m2 prior 
to each fraction of radiation. The solution of drug will be injected intravenously, 15 
minutes prior to delivery of radiation. The pharmacokinetics of systemically-injected 
amifostine will be determined in patients on the first day of radiotherapy. Serial blood 
samples will be obtained at predose, 1, 3, 5, 15, 30, 45 and 60 min, and at 2, 3, 4, 5 and 6 
hr after dosing in patients. We expect the studies will provide the important information 
on the expected drug levels, exposure (AUC) and disposition (clearance, volume of 
distribution, half-life) of amifostine and WR-1065 after systemic delivery of drug. We 
anticipate that systemic administration of amifostine will result in enhanced liver 
protection following radiotherapy, with systemic drug concentration shown in patients to 













6.1 Patients and study design 
 
A total of 5 patients (86.1 ± 24.3 kg) with intrahepatic cancer entered a phase I trial of 
dose escalating radiation therapy with systemic administration of amifostine. All of these 
patients have adequate hepatic function, defined by a normal prothrombin time (PT) 
which measures the extrinsic pathway of coagulation and partial thromboplastin time 
(PTT) which measures the intrinsic pathway of coagulation or correctable with Vitamin 
K, 0.8 < INR < 1.2. Characteristics of patients in this study are shown in Table 6.1. 
Patients received 340mg/m2 amifostine by IV bolus injection in one arm, 15 minutes 
prior to delivery of fractional radiation. The patient’s weight and height was determined 
at baseline and the patient body surface area was calculated using the method of Dubois 
method and the appropriate dose of amifostine will be calculated. The radiation therapy 
was delivered in 2 Gy fractions once daily five days a week. The pharmacokinetics of 
systemically-administered amifostine was determined in patients on the first day of 
radiotherapy. Serial blood samples were collected from a peripheral vein in another arm 
at 0 (predose), 1, 3, 5, 15, 30, 45 and 60min, and at 2, 3, 4, 5, and 6hr after dosing.  
6.2 Analytical methods[11-23] 
A high-performance liquid chromatography (HPLC) method with electrochemical 
detection was used for the analysis of amifostine and its active metabolite WR1065 in 
this clinical study. For the analysis of amifostine[23], whole-blood samples were 
centrifuged at 3400g and 0°C for 5min, and the plasma was separated and stored at -70°C 
for subsequent analysis. On the day of analysis, the plasma samples were thawed, WR-
80855 was added as an internal standard, an aliquot of 10% (w/v) trichloroacetic acid was 
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then added to an aliquot of the sample in the ratio of 2 to 5 (v/v) to precipitate the plasma 
proteins. Samples were mixed together thoroughly and centrifuged at 40,000g for 3mins 
at 0°C. A 20μl aliquot of supernatant was injected into the HPLC. For the analysis of 
WR1065[24], the whole-blood samples were placed into tubes, containing ice-cold 1.0 M 
perchloric acid and 2.7mM (1g/L) EDTA in a ratio of 1:1 (v/v), immediately after 
sampling. The mixture was then vortexed vigorously and centrifuged at 13,000g for 8min 
at 4°C. The supernatant was stored at -70°C for subsequent analysis. On the day of 
analysis (less than 24 hrs), the samples were thawed, and a 20μl aliquot was injected into 
the HPLC. Under the described method above, the limit of quantification of amifostine 
was 0.5μM. The amifostine to internal standard peak height ratios were linear over the 
amifostine concentration range of 0.5 to 50 μM (R2 = 0.999). The within- and between-
day accuracy of the assay varied from 5.8% to 7.4%, whereas the precision varied from 
6.9% to 3.3%. The limit of quantification of WR1065 was 0.05 μM. The WR1065 peak 
heights were linear over the WR1065 concentration range of 0.05 to 10 μM (R2 = 
0.9991). The interday variability (precision) of WR-1065 was less than 10% and the 
accuracy (bias) was less than 2% by measuring samples spiked with known 
concentrations of WR1065 at 0.1, 0.5, 2.4, 10 μM. All analysis were performed on a 
Waters (Milford, Massachusetts) 515 isocratic HPLC pump. Amifostine and the internal 
standard WR-80855 were detected by a BAS (West Lafayette, Indiana) LC-4C 
amperometric detector equipped with a thin film mercury-gold amalgam working 
electrode. The Hg/Au electrode potential was set at +0.15V with respect to the Ag/AgCl 
reference electrode and the range of the detector was set at 50nAFS. The WR1065 was 
detected by an ESA Coulochem III coulometric detector (Chelmsford, Massachusetts) 
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equipped with two porous graphite electrode in series which are set at +600mv (E2) and 
+200mv(E1) respectively vs α-hydrogen/palladium reference electrode. The detector’s 
range is set at 5μAFS. The analytical column, 4.6×250mm, 5μm particle size, C18 
Symmetry® Waters (Milford, Massachusetts), was operated at room temperature. The 
amifostine chromatography protocol consists of a mobile phase containing 0.1M 
chloroacetic acid sodium salt and 1.5mM sodium octyl sulfate, pH 3.0 at a flow rate of 
1ml/min. The WR-1065 chromatography protocol employed a mobile phase containing 
0.1M chloroacetic acid sodium salt, 4mM sodium octyl sulfate, pH 3.0, and 40% (v/v) 
methanol running at 1ml/min. Peak indentification was confirmed by comparing retention 
times in samples with authentic standards.  
6.3 Pharmacokinetic and covariate analysis 
PK parameters of each patient were determined for amifostine and WR1065 by 
noncompartmental analysis with WinNonlin 5.0 (Pharsight, Mountain View, California). 
These parameters include the area under the concentration-time curve (AUC), maximal 
concentration (Cmax), time to maximal concentration (tmax), volume of distribution (Vd), 
half-life (t1/2), and clearance (CL). In addition to that, the pharmacokinetics of amifostine 
and WR-1065 were also evaluated simultaneously for 5 liver cancer patients using 
NONMEM VI 1.0 (GloboMax LLC, Hanover, MD) by use of the first-order conditional 
estimation with η-ε interaction. S-plus 7.0 (Insightful software, Seattle, WA) was used to 
visualize the data and for the purpose of model diagnosis. Covariates were plotted 
independently against the interindividual variability ηi and the method of locally 
weighted regression was used to visualize potential relations. The following covariates 
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were tested: body weight, age, gender and prothrombin time (PT). A significant covariate 
that most reduces the objective function will be left in the model.  
6.4 Pharmacokinetic compartmental model 
Amifostine and its active metabolite WR-1065 concentration (µM) vs time (min) data 
were fitted simultaneously. The pharmacokinetic model used is schematically depicted in 
Figure 6.1. The amifostine data were described by a one-compartment model with first-
order elimination and IV bolus input, parameterized in terms of volume of distribution 
(V1) and clearance to WR-1065 (CL1). The formation of WR-1065 was described by a 
two-compartment model with the parameters of volume of the central compartment (V2), 
volume of the peripheral volume (V3), intercompartmental clearance (Q) and clearance of 
WR-1065 (CL2). Interindividual variability of the pharmacokinetic parameters was 
described by a exponential error model: θi = θTV ● eηi for both amifostine and WR-1065; 
where θi is the individual value of the parameter of the ith subject, θTV is the typical value 
of the population estimate of θi, ηi is the difference between them and is assumed to be a 
random variable with zero mean and variance ω2. The intraindividual variability was 
estimated by log-normal residual error model for both parent drug amifostine and 
metabolite. This means the model was fitted to log-transformed data and additive error 
term εi is a random variable with mean zero and variance σ2. 
6.5 Validation 
The final model was validated by inspection of goodness-of-fit plots of observed versus 
individually predicted, observed versus population predicted, weighted residuals versus 
population predictions, and weighted residuals versus time. Also the internal validity of 
the pharmacokinetic model was assessed by the nonparametric bootstrap method. 
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Parameters obtained with the bootstrap replicates were compared with the estimates 
obtained from the original data set. 
 Results 
Amifostine 
The plasma concentration-time curves of amifostine of 5 patients are shown in Figure 
6.2. The pharmacokinetic parameters of amifostine after an IV bolus dose from 
noncompartmental model with WinNonLin are summarized in Table 6.2. Following IV 
dose, the plasma concentration of amifostine decreased very rapidly, indicating that 
amifostine was rapidly converted into WR-1065. The mean values for half-life (3.4 ± 0.8 
min) and clearance (52.5 ± 9.9 mL/min/kg) indicate that amifostine is quickly cleared 
from the plasma. The mean value of volume of distribution at steady-state (Vss) of 8.4 L 
probably indicates that amifostine is primarily confined to the extracellular fluid. This is 
not unexpected given the very polar nature of amifostine. Population pharmacokinetic 
parameters from compartmental analysis are comparable to the results obtained from 
noncompartmental modeling. Based on the data collected and preliminary concentration 
vs time plot, we found the structural model of one-compartment with first-order 
elimination was the best fit for the data of amifostine. Clearance and volume of 
distribution of amifostine are 66.2 ± 3.89 ml/min/kg and 0.31 ± 0.04 L/kg respectively. 
Elimination half-life of amifostine is around 2 min. Inter-subject variability of clearance 
and volume of distribution of amifostine is low after including the covariate weight into 
the parameter model. Literaturely, amifostine has a small volume of distribution 3.5 - 8.7 
L, half-life t1/2 ≤ 15mins, clearance is in the range of 1.5 to 4.3 L/min, the value of AUC 






The plasma concentration-time curves of WR-1065 of 5 patients are shown in Figure 6.3. 
The pharmacokinetic parameters of WR-1065 after an IV bolus dose of amifostine of 
these five patients from noncompartmental modeling are summarized in Table 6.3. In our 
analysis of WR-1065 pharmacokinetics in human, we assumed that the dose of WR-1065 
is equal to that of amifostine which is 340mg/m2 based on the fact that all of amifostine is 
converted by metabolism to WR-1065. The time to reach maximal concentration for WR-
1065 is about 3 mins, confirms that amifostine is converted to WR-1065 very quickly. 
The maximal concentration of WR-1065 is lower than that of amifostine because the 
active metabolite has a larger volume of distribution. The clearance (81.7 ± 29.4 
mL/min/kg) of WR-1065 is greater than that of amifostine. The elimination half-life is 
around 1.5hr. Amifostine does not bind to plasma proteins; however, at least 50% of WR-
1065 is bound to proteins in plasma in the mouse [26]. WR-1065 can also rapidly form 
disulfides through oxidation. The large volume of distribution and the relatively long 
half-life indicates that WR-1065 is extensively bound in tissues. Two-compartment with 
first order elimination and absorption model was used for WR-1065 when we did 
population analysis compartmentally. Population estimates of clearance and volume of 
distribution of WR-1065 are larger than those of amifostine, indicating WR-1065 can 
form disulfide quickly and bound in tissues extensively. The half-life of WR-
1065(0.693/β) is much longer than that of amifostine. No significant covariate was found 
to be responsible for the inter-subject variability of the PK parameters of WR-1065 and 
inter-subject variability of the parameters was low. The only reported WR-1065 results 
from human study are Tmax between 1 and 4mins and Cmax between 7.2 and 22μM [25]. 
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Figure 6.4 and 6.5 show the diagnostic plots for amifostine and WR-1065 
pharmacokinetic model. The relationship between predicted and observed value appears a 
straight line and we didn’t observe significant trend on the plots of residuals vs predicted 
value for error model. The pharmacokinetic parameter values estimated by NONMEM 
and the method of bootstrapping are shown in Table 6.4. The fits of 100 bootstap 
replicates of the data set demonstrated the stability of the model. 
 
Discussion 
The pharmacokinetic study and a population pharmacokinetic model of amifostine and its 
metabolite WR-1065 are described. Furthermore, application of the population approach 
enables the characterization of interindividual variability as well as the source of this 
variability on the basis of covariate analysis. Because we have concentration data of both 
amifostine and WR-1065 and total 5 patients entered this study, we chose to estimate 
population PK parameters and simultaneously model amifostine and WR-1065 data. The 
selection of a pharmacokinetic model that fits the data best for each patient was based on 
the assessment of goodness-of-fit. Different weighting schemes (w = 1, 1/y, 1/y2) were 
also applied, but no improvement in fit was observed. Goodness of fit was evaluated by 
the relative standard error of each parameter estimated (%CV), coefficient of 
determination, and a plot of residuals. Based on the above limitations and individual 
variability in clinical study, we choose to fit amifostine data with noncompartmental 
model. For WR-1065, data were also fitted by noncompartmental model. We used 
noncompartmental method to obtain some PK parameters of amifostine and WR-1065 
because sometimes it is difficult to use one compartment model to fit all patients’ data, 
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and PK parameters from noncompartmental model can serve as good initial estimates for 
late compartmental population analysis. The results indicated PK parameters from these 
two different models are very comparable. As to the choice of estimation method in 
population analysis, first-order (FO) method is recommended only when there are few 
observations per individual (e.g., 2-3). Because first-order conditional estimation (FOCE) 
and first-order conditional estimation with interaction (FOCEI) can be very sensitive to 
starting values and we have rich data (11 points) for each individual,  we considered 
FOCEI method as our final estimate method for population analysis since FOCEI is 
appropriate whenever there are several observations per individual (> 5 points) and when 
the intraindividual error model depends on the individual mean, like proportional error or 
slope-intercept error model which are very common in the modeling of pharmacokinetic 
data. Proportional error and exponential error models are popular in dealing with 
intraindividual error, and they give the same results in estimation of parameters with 
NONMEM, however, the lognormal error model which we used in this study is better 
than above two because the geometric mean of an individual’s response is estimated with 
lognormal error model and arithmetic mean of the individual’s response is estimated with 
exponential error model, the lognormal error model is appropriate when the distribution 
of residuals is skewed and residual variability in the response is more than 30%. It is 
difficult to characterize the inter-subject variability (η) accurately in this study because 
we have a limited patients pool. A simultaneous fit is an excellent method for evaluating 
the overall parent and metabolite model because a priori mechanistic link between parent 
and metabolite is so strong in this study. It should be mentioned that non-linear 
regression programs (NONMEM) often give parameter estimates for unidentifiable 
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models and indicated that all was well therefore care must be taken to ensure all 
parameters are identifiable. When we fit simultaneously parent drug and metabolite 
concentrations it is not possible to estimate the volume of distribution of the metabolite 
and fraction of parent drug converted to metabolite separately. Without additional data 
we can either consider all drug is converted to metabolite or metabolite has same volume 
of distribution as parent drug. Based on the metabolic profile of amifostine, we think it is 
reasonable to assume that all amifostine is converted to metabolite (K10 = 0 in Figure 
6.1), that is the dose of WR-1065 is same as that of amifostine, which was confirmed by 
preliminary NONMEM run. The experimental results have shown amifostine is cleared 
from the plasma and converted to WR1065 very quickly. WR1065 is extensively bound 
in tissue and has a very large Vd. The large clearance of WR1065 indicates that it can be 
oxidized to disulfides rapidly. That is also the reason why we need to analyze WR1065 
samples immediately after collection. Because amifostine is more stable in plasma, we 
can process the samples in 1~2 days as long as the samples are stored under -70°C. In 
Summary, amifostine has a very short half-life, small volume of distribution and large 
clearance indicating that amifostine converted to WR1065 quickly; WR1065 has a longer 
half-life than amifostine, very large volume of distribution and large clearance indicating 





































cancer 2544 340 F 48 55 165 1.6 
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primary 2961 340 M 69 70 178 1.9 
Mean  3110   54 86 170 2.0 























LT 672 45.5 0.25 4.6 3.9 
CL 978 47.0 0.15 1.7 2.2 
JE 485 67.7 0.43 4.5 4.4 
DH 799 45.0 0.22 3.1 3.4 
RH 739 57.3 0.27 2.8 3.3 
Mean 735 52.5 0.26 3.3 3.4 























LT 5.0 28.5 562 54.4 5.3 34.8 68.0 
CL 1.0 40.4 635 72.3 8.5 49.9 81.2 
JE 3.0 16.2 336 97.5 19.3 58.4 137 
DH 3.0 11.7 289 125 19.6 72.6 109 
RH 3.0 35.3 710 59.5 7.1 41.8 82.2 
Mean 3.0 26.4 506 81.7 12.0 51.5 95.5 














PK Model Bootstrap Pharmacokinetic parameter 
Estimate                              CV% Mean                              CV% 
CLf (ml/min/kg) 66.2                                    5.8 65.7                                 6.7 
V1 (L/kg) 0.31                                  11.6 0.31                               11.4 
CLm (ml/min/kg)          90.8                                  14.1 91.3                                 14.9 
V2 (L/kg) 0.80                                  23.3 0.82                               24.3 
V3 (L/kg) 1.4                                    24.9 1.4                                  27.8 




η CLf (%) <1                                     <1 <1                                  <1 
η V1 (%) 24.8                                   59.5 22.1                               65.1 
η CLm (%) 7.13                                   58.2 5.98                               73.2 
η V2 (%) <1                                     <1 <1                                   <1 
η V3 (%) <1                                     <1 <1                                   <1 




ε Amifostine (µM) 0.53                                     13.5 0.52                               13.8 
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Figure 6.2.  Blood concentration versus time profiles of amifostine in five liver cancer patients. Observed data are 




















































































































Figure 6.3.  Blood concentration versus time profiles of WR-1065 in five liver cancer patients. Observed data are 































































Figure 6.4.  Observed versus predicted concentrations of (A) amifostine (circles) and (B) WR-1065 (squares), based on 










































Figure 6.5. Diagnostic plots for amifostine (A) and WR-1065 (B), where the weighted residuals are shown as a function of 
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Data for chapter 4 
Table A.1. Concentration of WR-1065 in liver, tumor, blood and ratio of concentration of WR-1065 in liver to tumor in tumor-bearing 
rats with systemic or regional dosing under central composite design 
 
Dose Time Route Rats Blood Liver Tumor Ratiolt Ratiolb Ratiotb
50 37.5 portal 1 0.154 3.08 4.56 0.68 20.00 29.61
50 37.5 portal 2 0.216 1.73 4.87 0.36 8.01 22.55
50 37.5 portal 3 0.18 1.93 4.81 0.40 10.72 26.72
50 37.5 femoral 1 0.21 1.69 4.11 0.41 8.05 19.57
50 37.5 femoral 2 0.274 1.47 4.54 0.32 5.36 16.57
50 37.5 femoral 3 0.23 1.32 3.74 0.35 5.74 16.26
125 21.5 portal 1 1.89 27.83 9.5 2.93 14.72 5.03
125 21.5 portal 2 2.08 26.2 11 2.38 12.60 5.29
125 21.5 portal 3 1.97 23.5 16.8 1.40 11.93 8.53
125 21.5 femoral 1 2.074 37.5 23.78 1.58 18.08 11.47
125 21.5 femoral 2 1.286 40.43 25.78 1.57 31.44 20.05
125 21.5 femoral 3 1.664 30.98 20.25 1.53 18.62 12.17
125 53.5 portal 1 0.284 5.43 14.08 0.39 19.12 49.58
125 53.5 portal 2 0.28 6.7 16.15 0.41 23.93 57.68
125 53.5 portal 3 0.516 6.95 13.25 0.52 13.47 25.68
125 53.5 femoral 1 0.94 4.89 10.11 0.48 5.20 10.76
125 53.5 femoral 2 0.42 3.5 8.37 0.42 8.33 19.93
125 53.5 femoral 3 0.56 4.52 9.88 0.46 8.07 17.64
275 15 portal 1 28.28 97.75 41.8 2.34 3.46 1.48




275 15 portal 3 41.36 149.9 85.2 1.76 3.62 2.06
275 15 femoral 1 29.56 97.78 46.73 2.09 3.31 1.58
275 15 femoral 2 75.12 138.4 84.25 1.64 1.84 1.12
275 15 femoral 3 45.84 113.1 70.3 1.61 2.47 1.53
275 37.5 portal 1 2.74 36.58 57.71 0.63 13.35 21.06
275 37.5 portal 2 2.81 59.61 37.93 1.57 21.21 13.50
275 37.5 portal 3 2.14 35.05 40.87 0.86 16.38 19.10
275 37.5 femoral 1 1.81 52.3 30.32 1.72 28.90 16.75
275 37.5 femoral 2 1.76 33.5 40.97 0.82 19.03 23.28
275 37.5 femoral 3 3.2 34.58 36.5 0.95 10.81 11.41
275 37.5 femoral 4 2.32 34.29 29.19 1.17 14.78 12.58
275 60 portal 1 3.05 22.87 26.5 0.86 7.50 8.69
275 60 portal 2 2.476 17.84 24.02 0.74 7.21 9.70
275 60 portal 3 2.34 14.5 25.63 0.57 6.20 10.95
275 60 femoral 1 1.438 12.76 26.49 0.48 8.87 18.42
275 60 femoral 2 1.625 13 21.6 0.60 8.00 13.29
275 60 femoral 3 2 11.11 13.84 0.80 5.56 6.92
425 21.5 portal 1 42.88 203.48 64.25 3.17 4.75 1.50
425 21.5 portal 2 51.52 164.45 24.35 6.75 3.19 0.47
425 21.5 portal 3 45.56 192.48 58.45 3.29 4.22 1.28
425 21.5 femoral 1 49.44 299.7 94.38 3.18 6.06 1.91
425 21.5 femoral 2 62.26 370.3 81.45 4.55 5.95 1.31
425 21.5 femoral 3 53.32 323.1 50.95 6.34 6.06 0.96
425 53.5 portal 1 4.52 17.81 29.17 0.61 3.94 6.45
425 53.5 portal 2 4.4 24.95 34.52 0.72 5.67 7.85
425 53.5 portal 3 3.97 21.38 33.85 0.63 5.39 8.53




425 53.5 femoral 2 3.27 20.68 32.77 0.63 6.32 10.02
425 53.5 femoral 3 5.44 21.56 34.23 0.63 3.96 6.29
500 37.5 portal 1 60.32 116.23 59.03 1.97 1.93 0.98
500 37.5 portal 2 57.5 138.93 64.43 2.16 2.42 1.12
500 37.5 portal 3 71.32 150.85 66.18 2.28 2.12 0.93
500 37.5 femoral 1 72.24 101.5 35.2 2.88 1.41 0.49
500 37.5 femoral 2 64.22 113.1 57.9 1.95 1.76 0.90












/***************************read and creat data***********************/ 
 
PROC IMPORT OUT= WORK.rats1  
            DATAFILE= "C:\Documents and Settings\zlu\Desktop\Rats Study\Rats1 
study\rats1 data\rats1.xls"  
            DBMS=EXCEL2000 REPLACE; 
     SHEET="Sheet2$";  
     GETNAMES=YES; 
RUN; 
proc sort data=rats1; 








      time='time(mins)' 
   liver='liver(nmols/g)' 
   tumor='tumor(nmols/g)' 
   ratio='L/T ratio' 
   blood='blood(uM)' 























proc glm data=rats1; 
model &y=&model/solution; 
%if &model=%str(vdum|dose|time) %then %do; 
contrast  'test for coincidence' vdum 1 -1, 
                                dose*vdum 1 -1, 
           time*vdum 1 -1, 
           dose*time*vdum 1 -1; 
%end; 
%else %do; 
contrast  'test for coincidence' vdum 1 -1, 
                                dose*vdum 1 -1, 
           time*vdum 1 -1, 
           dose*time*vdum 1 -1, 
           dose*dose*vdum 1 -1, 
            time*time*vdum 1 -1; 
%end; 
output out=rats1out p=yhat r=resid; 
run;quit; 
















/*********************data are splited***********/ 
%let a=f; 
%let model=%str(dose|time); 
data rats1&a; set rats1; 
where vein="&v"; 
run; 





proc glm data=rats1&a; 
model &y=&model; 
output out=rats1&a.out p=yhat r=resid; 
run;quit; 














/*************combine contour plot with spin surface plot************/ 
 
 
goptions reset=all ftext=swiss htext=6  gunit=pct border; 
data grid; 
do dose=50to 500 by 45; 







%let colors='yellow vibg cyan green lime gold orange red'; 
proc means data=grid noprint min max; 
var dose time ypred; 
output out=range min=dmin tmin ymin 













call symput('floor', int(ymin-4)); 
call symput('ceil',int(ymax+2)); 
run; 
proc sort data=grid; 
by time dose; 
run; 
data plane1 surf1; 
length function color $8; 
retain xsys ysys zsys '2'; 
set grid; 
by time; 
x=time; y=dose; z=&floor; 
if first.time then function='move';  






z=ypred; output surf1; 
run; 
proc sort data=grid; 
by dose time; 
run; 
data plane2 surf2; 
length function color $8; 
retain xsys ysys zsys '2'; 
set grid; 
by dose; 
x=time; y=dose; z=&floor; 







z=ypred; output surf2; 
run; 
data legend; 
length function color $8; 
retain xsys ysys zsys '2'; 
do legend=&ymin to (&ymax-&step) by &step; 












proc means data=rats1&a noprint mean nway; 
class dose time; 
var liver tumor ratio blood; 




merge rats1&a meanout; 
by dose time; 
retain color 'purple' xsys ysys zsys '2'; 
function='label'; x=time; y=dose; z=ratio; size=1; text='X';  output; 
function='move'; x=time; y=dose; z=rmean; size=1; output; 




set  surf1 surf2 plane1 plane2 legend back; 
run; 
data plotdata; 
dose=&dmin; time=&tmin; ypred=&floor; output; 





%do angle=0 %to 396 %by 36; 
%if &angle=0 %then %do; 
goptions reset=all gsfname=out dev=gifanim iteration=2 gsfmode=replace delay=100 
cback=black  transparency disposal=background  
         ftext=swissb htext=1.5; 
title height=2 color=white  'by femoral vein'; 
filename out 'C:\Documents and Settings\zlu\Desktop\Rats Study\Rats1 study\rats1 
results\ratiospinf.gif'; 
%end; 
%else %do; goptions gsfmode=append; %end; 




proc g3d data=plotdata; 
scatter dose*time=ypred/rotate=&angle shape='point' 
xticknum=4 yticknum=4 zticknum=6 zmin=&floor zmax=9.0 ctext=white  
annotate=annoall; 
label dose='Dose(mg/m2)' 
        time='Time(mins)' 



















proc sort data=rats1&a; 
by time dose; 
run; 
data anno2t; 
length color1-color5 $8; 
set rats1&a; 
by time; 
retain i 0 color1 'blue' color2 'green' color3 'yellow' color4 'orange' color5 'red' xsys ysys 
'2'; 
array colors{*} color1-color5; 
if first.time then i+1; 
function='symbol'; x=dose; y=ratio; text='X'; color=colors{i}; style='swiss'; size=1.5; 
output; 
run; 
ods listing close; 
ods html file='C:\Documents and Settings\zheng lu\Desktop\Rats Study\Rats1 study\rats1 
results\test.html' 





goptions reset=all cback=black transparency disposal=background ctext=white 
ftext=swissb htext=1.5; 
goptions device=win target=winprtc; 
title height=2 color=white  ' portal vein'; 
 
axis1 color=white 
        width=20 
  label=(font=swiss height=2) 
        value=(font=swiss height=2) 
        major=(width=2); 
axis2 color=white 
        width=20 
  label=(a=90 font=swiss height=2) 
        value=(font=swiss height=2) 
        major=(width=3 height=1) 
        order=0 to 8 by 1; 
symbol1 c=blue i=spline v=none w=30; 
symbol2 c=green i=spline v=none w=30; 
symbol3 c=yellow i=spline v=none w=30; 
symbol4 c=orange i=spline v=none w=30; 
symbol5 c=red i=spline v=none w=30; 
proc gplot data=grid2t; 
plot ypred*dose=time/anno=anno2t haxis=axis1 vaxis=axis2; 
label dose='Dose(mg/m2)' 
        time='Time(mins)' 
        ypred='Ratio'; 
run;quit;  
ods html close; 
ods listing; 
 




do time=15 to 60 by 5; 






proc sort data=rats1&a; 
by dose time; 
run; 
data anno2t; 





retain i 0 color1 'blue' color2 'green' color3 'yellow' color4 'orange' color5 'red' xsys ysys 
'2'; 
array colors{*} color1-color5; 
if first.dose then i+1; 
function='symbol'; x=time; y=ratio; text='X'; color=colors{i}; style='swiss'; size=1.5; 
output; 
run; 
ods listing close; 
ods html file='C:\Documents and Settings\zlu\Desktop\Rats Study\Rats1 study\rats1 
results\test.html' 
         gpath='C:\Documents and Settings\zlu\Desktop\Rats Study\Rats1 study\rats1 
results\'; 
 
goptions reset=all cback=black transparency disposal=background ctext=white 
ftext=swissb htext=1.5; 
goptions device=win target=winprtc; 
title height=2 color=white  ' portal vein'; 
 
axis1 color=white 
        width=20 
  label=(font=swiss height=2) 
        value=(font=swiss height=2) 
        major=(width=2); 
axis2 color=white 
        width=20 
  label=(a=90 font=swiss height=2) 
        value=(font=swiss height=2) 
        major=(width=3 height=1) 
        order=0 to 8 by 1; 
symbol1 c=blue i=spline v=none w=30; 
symbol2 c=green i=spline v=none w=30; 
symbol3 c=yellow i=spline v=none w=30; 
symbol4 c=orange i=spline v=none w=30; 
symbol5 c=red i=spline v=none w=30; 
proc gplot data=grid2t; 
plot ypred*time=dose/anno=anno2t haxis=axis1 vaxis=axis2; 
label dose='Dose(mg/m2)' 
        time='Time(mins)' 
        ypred='Ratio'; 
run;quit;  






Data for chapter 5 
Table C.1. Concentration of WR-1065 in liver, tumor, blood and ratio of concentration of WR-1065 in liver to tumor in tumor-bearing 
rats with intravenous or subcutaneous dosing under central composite design 
 
Dose Time Route Liver1 Liver2 Tumor1 Tumor2 Ratiolt Blood Ratiolb Ratiotb 
100 32.5 FV 1.95 11.7 2.24 13.44 0.87 4.87 2.4 2.76
100 32.5 FV 1.975 11.85 2.49 14.94 0.79 1.85 6.41 8.08
100 32.5 FV 0.93 5.58 1.6 9.6 0.58 1.73 3.23 5.55
100 32.5 SC 0.48 2.88 0.921 5.526 0.52 1.64 1.76 3.37
100 32.5 SC 0.66 3.96 0.736 4.416 0.9 2.79 1.42 1.58
100 32.5 SC 0.81 4.86 1.335 8.01 0.61 2.93 1.66 2.73
1000 32.5 FV 66.47 398.82 19.92 119.52 3.34 159.52 2.5 0.75
1000 32.5 FV 53.76 322.56 20.89 125.34 2.57 94.72 3.41 1.32
1000 32.5 FV 53.41 320.46 23.75 142.5 2.25 129.8 2.47 1.1
1000 32.5 SC 40.63 243.78 19.71 118.26 2.06 85.5 2.85 1.38
1000 32.5 SC 47.51 285.06 13.46 80.76 3.53 112.47 2.53 0.72
1000 32.5 SC 54.77 328.62 24.41 146.46 2.24 81.22 4.05 1.8
550 5 FV 46.19 277.14 7.24 43.44 6.38 131.64 2.11 0.33
550 5 FV 44.8 268.8 6.53 39.18 6.86 167.1 1.61 0.23
550 5 FV 50.81 304.86 5.59 33.54 9.09 108.03 2.82 0.31
550 32.5 FV 16.71 100.26 6.64 39.84 2.52 25.36 3.95 1.57
550 32.5 FV 21.57 129.42 7.2 43.2 3 31.02 4.17 1.39
550 32.5 FV 21.43 128.58 8.15 48.9 2.63    
550 32.5 FV 34.75 208.5 13.87 83.22 2.51 63.82 3.27 1.3
550 32.5 FV 41.72 250.32 7.02 42.12 5.94 51.02 4.91 0.83
550 60 FV 14.47 86.82 7.19 43.14 2.01 42.82 2.03 1.01
550 60 FV 22.18 133.08 8.59 51.54 2.58 36.94 3.6 1.4
550 5 SC 6.74 40.44 1.51 9.06 4.46 27.09 1.49 0.33




550 5 SC 6.86 41.16 1.39 8.34 4.94 22.3 1.85 0.37
550 32.5 SC 15.51 93.06 3.62 21.72 4.28 17.15 5.43 1.27
550 32.5 SC 15.71 94.26 3.91 23.46 4.02 26.25 3.59 0.89
550 32.5 SC 18.82 112.92 4.37 26.22 4.31    
550 60 SC 18.31 109.86 11.52 69.12 1.59 37.75 2.91 1.83
550 60 SC 12.72 76.32 8.71 52.26 1.46 21.99 3.47 2.38
550 60 SC 17.68 106.08 9.54 57.24 1.85 31.68 3.35 1.81
232 13.05 FV 12.98 77.88 8.37 50.22 1.55    
232 13.05 FV 11.3 67.8 2.84 17.04 3.98 18.19 3.73 0.94
232 13.05 FV 10.3 61.8 4.29 25.74 2.4 46.44 1.33 0.55
232 13.05 FV 14.39 86.34 2.94 17.64 4.89 35.65 2.42 0.49
232 13.05 SC 3.65 21.9 2 12 1.83 14.45 1.52 0.83
232 13.05 SC 4.39 26.34 1.59 9.54 2.76 10.94 2.41 0.87
232 13.05 SC 6.53 39.18 2.75 16.5 2.37 17.79 2.2 0.93
232 51.95 FV 3.68 22.08 2.93 17.58 1.26 4.77 4.63 3.69
232 51.95 FV 1.37 8.22 2.19 13.14 0.63 3.51 2.34 3.74
232 51.95 FV 2.823 16.938 3.28 19.68 0.86 5.48 3.09 3.59
232 51.95 SC 2.07 12.42 2.21 13.26 0.94 5.29 2.35 2.51
232 51.95 SC 2.3 13.8 2.053 12.318 1.12 5.322 2.59 2.31
232 51.95 SC 1.32 7.92 1.42 8.52 0.93 5.18 1.53 1.64
868 51.95 FV 21.54 129.24 12.38 74.28 1.74 35.24 3.67 2.11
868 51.95 FV 20.43 122.58 10.33 61.98 1.98    
868 51.95 FV 16.99 101.94 9.93 59.58 1.71 31.81 3.2 1.87
868 51.95 SC 18.57 111.42 11.19 67.14 1.66 58.15 1.92 1.15
868 51.95 SC 27.01 162.06 17.156 102.936 1.57    
868 51.95 SC 40.79 244.74 17.18 103.08 2.37 77.03 3.18 1.34
868 13.05 FV 83.89 503.34 11.12 66.72 7.54 134.1 3.75 0.5
868 13.05 FV 94.39 566.34 11.52 69.12 8.19 192.7 2.94 0.36
868 13.05 FV 65.93 395.58 12.49 74.94 5.28 249.46 1.59 0.3
868 13.05 FV 90.2 541.2 15.22 91.32 5.93    
868 13.05 SC 22.68 136.08 3.91 23.46 5.8 65.74 2.07 0.36
868 13.05 SC 24.27 145.62 4.29 25.74 5.66 87.82 1.66 0.29








SAS codes for chapter 5 
 
 
/***************************read and creat data***********************/ 
 
PROC IMPORT OUT= WORK.rats2  
            DATAFILE= "C:\Documents and Settings\zlu\Desktop\Rats Study\Rats2 
study\rats2 data\062206"  
            DBMS=EXCEL2000 REPLACE; 
     SHEET="sheet1$";  
     GETNAMES=YES; 
RUN; 
proc sort data=rats2; 







      time='time(mins)' 
   liver2='liver(nmols/g)' 
   tumor2='tumor(nmols/g)' 
   ratio='L/T ratio' 
   blood='blood(uM)' 

























proc glm data=rats1; 
model &y=&model/solution; 
%if &model=%str(vdum|dose|time) %then %do; 
contrast  'test for coincidence' vdum 1 -1, 
                                dose*vdum 1 -1, 
           time*vdum 1 -1, 
          dose*time*vdum 1 -1; 
%end; 
%else %do; 
contrast  'test for coincidence' vdum 1 -1, 
                                dose*vdum 1 -1, 
           time*vdum 1 -1, 
          dose*time*vdum 1 -1, 
          dose*dose*vdum 1 -1, 
           time*time*vdum 1 -1; 
%end; 
output out=rats1out p=yhat r=resid; 
run;quit; 






















data rats2&a; set rats2; 
where route="&r"; 
run; 
proc transreg data=rats1&a details; 
model boxcox(&y)=identity(&model); 
run; 
proc rsreg data=rats2&a; 
model &y=dose time/lackfit press; 
run; 
proc glm data=rats2&a; 
model &y=&model; 
output out=rats1&a.out p=yhat r=resid; 
run;quit; 


























proc sort data=rats2&a; 
by time dose; 
run; 
data anno2t; 





retain i 0 color1 'blue' color2 'green' color3 'yellow' color4 'orange' color5 'red' xsys ysys 
'2'; 
array colors{*} color1-color5; 
if first.time then i+1; 
function='symbol'; x=dose; y=blood; text='X'; color=colors{i}; style='swiss'; size=1.5; 
output; 
run; 
ods listing close; 
ods html file='C:\Documents and Settings\zlu\Desktop\Rats Study\Rats2 study\rats2 
results\test.html' 
         gpath='C:\Documents and Settings\zlu\Desktop\Rats Study\Rats2 study\rats2 
results\'; 
 
goptions reset=all cback=black transparency disposal=background ctext=white 
ftext=swissb htext=1.5; 
goptions device=win target=winprtc; 
title height=2 color=white  ' FV'; 
 
axis1 color=white 
        width=20 
  label=(font=swiss height=2) 
        value=(font=swiss height=2) 
        major=(width=2); 
axis2 color=white 
        width=20 
  label=(a=90 font=swiss height=2) 
        value=(font=swiss height=2) 
        major=(width=3 height=1) 
        order=0 to 400 by 100; 
symbol1 c=blue i=spline v=none w=30; 
symbol2 c=green i=spline v=none w=30; 
symbol3 c=yellow i=spline v=none w=30; 
symbol4 c=orange i=spline v=none w=30; 
symbol5 c=red i=spline v=none w=30; 
proc gplot data=grid2t; 
plot ypred*dose=time/anno=anno2t haxis=axis1 vaxis=axis2; 
label dose='Dose(mg/m2)' 
        time='Time(mins)' 
        ypred='Blood(uM)'; 
run;quit;  









do time=5 to 60 by 5; 







proc sort data=rats2&a; 
by dose time; 
run; 
data anno2t; 
length color1-color5 $8; 
set rats2&a; 
by dose; 
retain i 0 color1 'blue' color2 'green' color3 'yellow' color4 'orange' color5 'red' xsys ysys 
'2'; 
array colors{*} color1-color5; 
if first.dose then i+1; 
function='symbol'; x=time; y=blood; text='X'; color=colors{i}; style='swiss'; size=1.5; 
output; 
run; 
ods listing close; 
ods html file='C:\Documents and Settings\zlu\Desktop\Rats Study\Rats2 study\rats2 
results\test.html' 
         gpath='C:\Documents and Settings\zlu\Desktop\Rats Study\Rats2 study\rats2 
results\'; 
 
goptions reset=all cback=black transparency disposal=background ctext=white 
ftext=swissb htext=1.5; 
goptions device=win target=winprtc; 
title height=2 color=white  'FV'; 
 
axis1 color=white 
        width=20 
  label=(font=swiss height=2) 
        value=(font=swiss height=2) 
        major=(width=2); 
axis2 color=white 
        width=20 
  label=(a=90 font=swiss height=2) 
        value=(font=swiss height=2) 
        major=(width=3 height=1) 
        order=0 to 400 by 100; 
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symbol1 c=blue i=spline v=none w=30; 
symbol2 c=green i=spline v=none w=30; 
symbol3 c=yellow i=spline v=none w=30; 
symbol4 c=orange i=spline v=none w=30; 
symbol5 c=red i=spline v=none w=30; 
proc gplot data=grid2t; 
plot ypred*time=dose/anno=anno2t haxis=axis1 vaxis=axis2; 
label dose='Dose(mg/m2)' 
        time='Time(mins)' 
        ypred='Blood(uM)'; 
run;quit;  





/*************combine contour plot with spin surface plot************/ 
 
 
goptions reset=all ftext=swiss htext=6  gunit=pct border; 
data grid; 
do dose=50to 500 by 45; 







%let colors='yellow vibg cyan green lime gold orange red'; 
proc means data=grid noprint min max; 
var dose time ypred; 
output out=range min=dmin tmin ymin 
















proc sort data=grid; 
by time dose; 
run; 
data plane1 surf1; 
length function color $8; 
retain xsys ysys zsys '2'; 
set grid; 
by time; 
x=time; y=dose; z=&floor; 
if first.time then function='move';  






z=ypred; output surf1; 
run; 
proc sort data=grid; 
by dose time; 
run; 
data plane2 surf2; 
length function color $8; 
retain xsys ysys zsys '2'; 
set grid; 
by dose; 
x=time; y=dose; z=&floor; 







z=ypred; output surf2; 
run; 
data legend; 
length function color $8; 
retain xsys ysys zsys '2'; 
do legend=&ymin to (&ymax-&step) by &step; 












proc means data=rats1&a noprint mean nway; 
class dose time; 
var liver tumor ratio blood; 




merge rats1&a meanout; 
by dose time; 
retain color 'purple' xsys ysys zsys '2'; 
function='label'; x=time; y=dose; z=ratio; size=1; text='X';  output; 
function='move'; x=time; y=dose; z=rmean; size=1; output; 




set  surf1 surf2 plane1 plane2 legend back; 
run; 
data plotdata; 
dose=&dmin; time=&tmin; ypred=&floor; output; 





%do angle=0 %to 360 %by 10; 
%if &angle=0 %then %do; 
goptions reset=all gsfname=out dev=gifanim gsfmode=replace delay=100 cback=black  
transparency disposal=background  
         ftext=swissb htext=1.5; 
title height=2 color=white  'by portal vein'; 
filename out 'C:\Documents and Settings\zlu\Desktop\Rats Study\Rats1 study\rats1 
results\ratiospin.gif'; 
%end; 
%else %do; goptions gsfmode=append; %end; 
%if &angle=360 %then %do; goptions gepilog='3B'x; 
%end; 
proc g3d data=plotdata; 
scatter dose*time=ypred/rotate=&angle shape='point' 





        time='Time(mins)' 






/*************Model selection and confidence interval***************/ 
 
PROC IMPORT OUT= WORK.rats2  
            DATAFILE= "C:\Documents and Settings\zlu\Desktop\Rats Study\Rats2 
study\rats2 data\062206.xls"  
            DBMS=EXCEL REPLACE; 
     SHEET="Sheet1$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 













proc sort data=rats2trans; 
by dose time route; 
run; 
proc means data=rats2trans noprint; 
var liver2 tumor2 ratiolt blood ratiolb ratiotb lliver ltumor lratiolt lblood lratiolb lratiotb; 
by dose time route; 
output out=rats2transstd std=sliver2 stumor2 sratiolt sblood sratiolb sratiotb slliver 
sltumor slratiolt slblood slratiolb slratiotb; 
run; 
data rats2wt; 
array stds {*} sliver2 stumor2 sratiolt sblood sratiolb sratiotb slliver sltumor slratiolt 
slblood slratiolb slratiotb; 
array wts {*} wliver2 wtumor2 wratiolt wblood wratiolb wratiotb wlliver wltumor 
wlratiolt wlblood wlratiolb wlratiotb; 
 
 166 
merge rats2trans rats2transstd; 
by dose time route; 
do i=1 to dim(stds); 
wts{i}=1/stds{i}; 
end; 
drop i _type_ _freq_; 
run; 
proc sort data=rats2wt; 
by route dose time; 
run; 
data rats2reg; 
array vars{*} liver2 tumor2 ratiolt blood ratiolb ratiotb lliver ltumor lratiolt lblood 
lratiolb lratiotb; 
set rats2wt; 











if last.dose then do; 
do i=1 to dim(vars); 
vars{i}=.; 
end; 










proc reg data=rats2reg; 
model lblood=dose time dose2 time2 td rdum rdose rtime rtd rdose2 
rtime2/selection=stepwise sle=0.05 sls=0.05; 
weight wlblood; 
output out=rats2wtregb p=yhat r=resid lclm=yl uclm=yu; 
run; quit; 
proc sort data=rats2trans; 
 
 167 
by route dose time; 
run; 
proc sort data=rats2wtregb; 
by route dose time; 
run; 
data anno1; 
length color1-color5 $8; 
set rats2trans(where=(blood gt .)); 
by route dose; 
retain i 0 color1 'blue' color2 'green' color3 'yellow' color4 'orange' color5 'red' xsys ysys 
'2'; 
array colors{*} color1-color5; 
if first.route then i=0; 
if first.dose then i+1; 














keep dose time route yl yu; 
run; 
data anno2; 
length color1-color5 $8; 
set rats2wtregbanno; 
by route dose; 
retain i 0 color1 'blue' color2 'green' color3 'yellow' color4 'orange' color5 'red' xsys ysys 
'2'; 
array colors{*} color1-color5; 
if first.route then i=0; 
if first.dose then i+1; 
retain j -0.1; 
if first.dose then j+0.1; 
function='move'; x=time+j; y=yu; color=colors{i}; style='swiss'; size=1.5; output;  
function='draw'; x=time+j; y=yl; color=colors{i}; style='swiss'; size=1.5; output; 
run; 
data annoall; 




proc sort data=annoall; 
by route dose time; 
run; 
 
ods listing close; 
ods html file='C:\Documents and Settings\zlu\Desktop\Rats Study\Rats2 study\rats2 
results\122906\test.html' 
         gpath='C:\Documents and Settings\zlu\Desktop\Rats Study\Rats2 study\rats2 
results\122906'; 
 
goptions reset=all cback=white transparency disposal=background ctext=black 
ftext=swissb htext=2; 




        width=30 
  label=(font=swiss height=2.5) 
        value=(font=swiss height=2.5) 
        major=(width=2.5); 
axis2 color=black 
        width=30 
  label=(a=90 font=swiss height=2.5) 
        value=(font=swiss height=2.5) 
        major=(width=3.5 height=1.5) 
        order=0 to 400 by 100; 
symbol1 c=blue i=spline v=none w=35; 
symbol2 c=green i=spline v=none w=35; 
symbol3 c=yellow i=spline v=none w=35; 
symbol4 c=orange i=spline v=none w=35; 
symbol5 c=red i=spline v=none w=35; 
proc gplot data=rats2wtregbo; 
plot yhat*time=dose/anno=annoall haxis=axis1 vaxis=axis2; 
by route; 
label dose='Dose(mg/m2)' 
      time='Time(mins)' 
      yhat='Blood(uM)'; 
run;quit;  










Data for chapter 6 
Table E.1. Concentrations of amifostine and WR-1065 in plasma/blood of 5 patients and covariates prepared for NONMEM analysis 
 
C  
PK modeling for Amifostine and active metabolite WR1065 after single IV bolus  dose of 
Amifostine   
C  
No. of subjects= 5, Dose = umols/kg, DV= Plasma concentration of Amifostine and WR1065(uM), 
Time=mins  
CID Time OBS DV Anum AMT Sex WT Age CMT EVID MDV 
1 0 0 0 1 30.6 0 110.23 44 1 1 1
1 1 187 5.231109 1 0 0 110.23 44 1 0 0
1 1 14.24 2.656055 1 0 0 110.23 44 2 0 0
1 5 85.55 4.449101 1 0 0 110.23 44 1 0 0
1 5 28.49 3.349553 1 0 0 110.23 44 2 0 0
1 15 12.1 2.493205 1 0 0 110.23 44 1 0 0
1 15 13.43 2.597491 1 0 0 110.23 44 2 0 0
1 30 1.03 0.029559 1 0 0 110.23 44 1 0 0
1 30 3.25 1.178655 1 0 0 110.23 44 2 0 0
1 45 1.19 0.173953 1 0 0 110.23 44 2 0 0
1 60 0.83 -0.18633 1 0 0 110.23 44 2 0 0
1 120 0.4 -0.91629 1 0 0 110.23 44 2 0 0
1 180 0.35 -1.04982 1 0 0 110.23 44 2 0 0
1 240 0.13 -2.04022 1 0 0 110.23 44 2 0 0
2 0 0 0 1 45.9 0 55.4 48 1 1 1
2 1 476 6.165418 1 0 0 55.4 48 1 0 0
2 1 40.41 3.699077 1 0 0 55.4 48 2 0 0
2 5 41.5 3.725693 1 0 0 55.4 48 1 0 0
2 5 23.87 3.172622 1 0 0 55.4 48 2 0 0
2 15 4.46 1.495149 1 0 0 55.4 48 1 0 0




2 30 2.37 0.86289 1 0 0 55.4 48 2 0 0
2 45 1.85 0.615186 1 0 0 55.4 48 2 0 0
2 60 1.32 0.277632 1 0 0 55.4 48 2 0 0
2 120 0.51 -0.67334 1 0 0 55.4 48 2 0 0
2 180 0.27 -1.30933 1 0 0 55.4 48 2 0 0
2 240 0.25 -1.38629 1 0 0 55.4 48 2 0 0
2 300 0.16 -1.83258 1 0 0 55.4 48 2 0 0
2 360 0.15 -1.89712 1 0 0 55.4 48 2 0 0
3 0 0 0 1 32.8 1 110 54 1 1 1
3 1 167 5.117994 1 0 1 110 54 1 0 0
3 1 2.173 0.776109 1 0 1 110 54 2 0 0
3 3 126.17 4.83763 1 0 1 110 54 1 0 0
3 3 16.176 2.783529 1 0 1 110 54 2 0 0
3 5 44.12 3.786913 1 0 1 110 54 1 0 0
3 5 14.357 2.664238 1 0 1 110 54 2 0 0
3 15 6.56 1.880991 1 0 1 110 54 1 0 0
3 15 6.554 1.880076 1 0 1 110 54 2 0 0
3 30 1.734 0.550431 1 0 1 110 54 1 0 0
3 30 2.436 0.890357 1 0 1 110 54 2 0 0
3 45 1.222 0.200489 1 0 1 110 54 2 0 0
3 60 0.7068 -0.34701 1 0 1 110 54 2 0 0
3 120 0.205 -1.58475 1 0 1 110 54 2 0 0
3 240 0.1417 -1.95404 1 0 1 110 54 2 0 0
3 360 0.061 -2.79688 1 0 1 110 54 2 0 0
4 0 0 0 1 36 0 85 53 1 1 1
4 1 325.6 5.78567 1 0 0 85 53 1 0 0
4 1 4.675 1.542229 1 0 0 85 53 2 0 0
4 3 169.43 5.13244 1 0 0 85 53 1 0 0
4 3 11.69 2.458734 1 0 0 85 53 2 0 0
4 5 81.93 4.405865 1 0 0 85 53 1 0 0
4 5 11.455 2.438426 1 0 0 85 53 2 0 0
4 15 3.34 1.205971 1 0 0 85 53 1 0 0




4 30 0.994 -0.00602 1 0 0 85 53 1 0 0
4 30 1.97 0.678034 1 0 0 85 53 2 0 0
4 45 0.849 -0.1637 1 0 0 85 53 2 0 0
4 60 0.56 -0.57982 1 0 0 85 53 2 0 0
4 120 0.237 -1.4397 1 0 0 85 53 2 0 0
4 240 0.121 -2.11196 1 0 0 85 53 2 0 0
4 360 0.105 -2.25379 1 0 0 85 53 2 0 0
5 0 0 0 1 42.3 1 70 69 1 1 1
5 1 342.1 5.835103 1 0 1 70 69 1 0 0
5 1 10.7 2.370244 1 0 1 70 69 2 0 0
5 3 141.4 4.951593 1 0 1 70 69 1 0 0
5 3 35.25 3.562466 1 0 1 70 69 2 0 0
5 5 58.21 4.064057 1 0 1 70 69 1 0 0
5 5 34.67 3.545875 1 0 1 70 69 2 0 0
5 15 5 1.609438 1 0 1 70 69 1 0 0
5 15 13.78 2.623218 1 0 1 70 69 2 0 0
5 30 0.272 -1.30195 1 0 1 70 69 1 0 0
5 30 4.67 1.541159 1 0 1 70 69 2 0 0
5 45 2.255 0.81315 1 0 1 70 69 2 0 0
5 60 1.267 0.236652 1 0 1 70 69 2 0 0
5 120 0.59 -0.52763 1 0 1 70 69 2 0 0
5 240 0.174 -1.7487 1 0 1 70 69 2 0 0







NONMEM codes for chapter 6 
 
$PROBLEM Parent drug & active metabolite    ;Units: Time=mins, 
Concentration=uM(umols/L), Amount=umols/kg 
                                             ;Age=yrs, Weight=kg 
                                             ;Sex=1(is male) or 0(is female) 
                                             ;Anum=1(is EC) or 2(is FL) 
$DATA AW2LN.CSV IGNORE=C  
$INPUT ID TIME OBS DV ANUM AMT SEX WT AGE BSA PT PTT INR CMT 
EVID MDV 
 



































































0 FIX  
 
 




$TABLE ID TIME OBS AMT SEX WT AGE BSA PT PTT INR CMT IPRED IRES 
IWRES ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 






S-plus codes for chapter 6 
 
# INPUT DATA 
amiwrec=read.table('C:\\Documents and Settings\\zlu\\Desktop\\Human 








hist(amiwrecm$OBS, prob=T, ylab='Probability', xlab='Untransformed Observation') 
lines(density(amiwrecm$OBS),col=8, lwd=3,lty=3) 
qqnorm(amiwrecm$OBS, pch=16, col=2,ylab='Untransformed Observation' ) 
qqline(amiwrecm$OBS, lwd=3, col=5) 
 
hist(amiwrecm$DV, prob=T, ylab='Probability', xlab='Transformed Observation') 
lines(density(amiwrecm$DV),col=8, lwd=3,lty=3) 
qqnorm(amiwrecm$DV, pch=16, col=2,ylab='Transformed Observation' ) 
qqline(amiwrecm$DV, lwd=3, col=5) 
 
 
# DISTRIBUTION OF RESIDUALS 
graphsheet() 
par(mfrow=c(2,2), mar=c(5,5,3,3)) 
hist(amiwrecm$IWRE,prob=T, ylab='Probability', xlab='IWRE') 
lines(density(amiwrecm$IWRE),col=8, lwd=3,lty=3) 
qqnorm(amiwrecm$IWRE, pch=16, col=2,ylab='IWRE' ) 





qqnorm(amiwrecm$WRES, pch=16, col=2,ylab='WRES') 
qqline(amiwrecm$WRES, lwd=3, col=5) 
 
 
# RESIDUAL PLOTS 
graphsheet() 
par(mfrow=c(2,2),mar=c(5,5,4,4)) 
plot(amiwrecm$IPRE, amiwrecm$IWRE, pch=16, col=2, xlab='IPRE', ylab='IWRES', 




abline(h=c(-2,2), lwd=3, col=5, lty=4) 
lines(lowess(amiwrecm$IPRE, amiwrecm$IWRE),lwd=2, col=3) 
plot(amiwrecm$TIME, amiwrecm$IWRE, pch=16, col=2, xlab='TIME', ylab='IWRES', 
xlim=c(0,400), ylim=c(-3.5,3.5), cex=1.2) 
abline(h=0,lwd=3, col=5) 
#abline(h=c(-2.5,2.5), lwd=3, col=5, lty=4) 
lines(lowess(amiwrecm$TIME, amiwrecm$IWRE),lwd=2, col=3) 
plot(amiwrecm$PRED, amiwrecm$WRES, pch=16, col=2, xlab='PRED', ylab='WRES', 
xlim=c(-1.5,3), ylim=c(-4,4), cex=1.2) 
abline(h=0,lwd=3, col=5) 
abline(h=c(-2,2), lwd=3, col=5, lty=4) 
lines(lowess(amiwrecm$PRED, amiwrecm$WRES),lwd=2, col=3) 
plot(amiwrecm$TIME, amiwrecm$WRES, pch=16, col=2, xlab='TIME', ylab='WRES', 
xlim=c(0,400), ylim=c(-4,4), cex=1.2) 
abline(h=0,lwd=3, col=5) 
#abline(h=c(-2.5,2.5), lwd=3, col=5, lty=4) 
lines(lowess(amiwrecm$TIME, amiwrecm$WRES),lwd=2, col=3) 
 
# ETA PLOTS (1) 
graphsheet() 
par(mfrow=c(6,3), mar=c(8,8,4,4)) 
plot(amiwrecm$WT, amiwrecm$ETA1, xlab='Weight(kg)',ylab='ETACL1', col=2, 
pch=16, cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA1), col=5, lwd=3) 
plot(amiwrecm$AGE, amiwrecm$ETA1, xlab='Age(yrs)',ylab='ETACL1', col=2, pch=16, 
cex=1.0) 




plot(amiwrecm$WT, amiwrecm$ETA2, xlab='Weight(kg)',ylab='ETAV1', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA2), col=5, lwd=3) 
plot(amiwrecm$AGE, amiwrecm$ETA2, xlab='Age(yrs)',ylab='ETAV1', col=2, pch=16, 
cex=1.0) 




plot(amiwrecm$WT, amiwrecm$ETA3, xlab='Weight(kg)',ylab='ETACLM', col=2, 
pch=16, cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA3), col=5, lwd=3) 
plot(amiwrecm$AGE, amiwrecm$ETA3, xlab='Age(yrs)',ylab='ETACLM', col=2, 
pch=16, cex=1.0) 






plot(amiwrecm$WT, amiwrecm$ETA4, xlab='Weight(kg)',ylab='ETAQ', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA4), col=5, lwd=3) 
plot(amiwrecm$AGE, amiwrecm$ETA4, xlab='Age(yrs)',ylab='ETAQ', col=2, pch=16, 
cex=1.0) 




plot(amiwrecm$WT, amiwrecm$ETA5, xlab='Weight(kg)',ylab='ETAV2', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA5), col=5, lwd=3) 
plot(amiwrecm$AGE, amiwrecm$ETA5, xlab='Age(yrs)',ylab='ETAV2', col=2, pch=16, 
cex=1.0) 




plot(amiwrecm$WT, amiwrecm$ETA6, xlab='Weight(kg)',ylab='ETAV3', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA6), col=5, lwd=3) 
plot(amiwrecm$AGE, amiwrecm$ETA6, xlab='Age(yrs)',ylab='ETAV3', col=2, pch=16, 
cex=1.0) 




# ETA PLOTS (2) 
graphsheet() 
par(mfrow=c(6,3), mar=c(8,8,4,4)) 
plot(amiwrecm$PT, amiwrecm$ETA1, xlab='PT',ylab='ETACL1', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$PT, amiwrecm$ETA1), col=5, lwd=3) 
plot(amiwrecm$PTT, amiwrecm$ETA1, xlab='PTT',ylab='ETACL1', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$PTT, amiwrecm$ETA1), col=5, lwd=3) 
plot(amiwrecm$INR, amiwrecm$ETA1, xlab='INR',ylab='ETACL1', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$INR, amiwrecm$ETA1), col=5, lwd=3) 
 
plot(amiwrecm$PT, amiwrecm$ETA2, xlab='PT',ylab='ETAV1', col=2, pch=16, cex=1.0) 
lines(lowess(amiwrecm$PT, amiwrecm$ETA2), col=5, lwd=3) 
 
 177 
plot(amiwrecm$PTT, amiwrecm$ETA2, xlab='PTT',ylab='ETAV1', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$PTT, amiwrecm$ETA2), col=5, lwd=3) 
plot(amiwrecm$INR, amiwrecm$ETA2, xlab='INR',ylab='ETAV1', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$INR, amiwrecm$ETA2), col=5, lwd=3) 
 
plot(amiwrecm$PT, amiwrecm$ETA3, xlab='PT',ylab='ETACLM', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$PT, amiwrecm$ETA3), col=5, lwd=3) 
plot(amiwrecm$PTT, amiwrecm$ETA3, xlab='PTT',ylab='ETACLM', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$PTT, amiwrecm$ETA3), col=5, lwd=3) 
plot(amiwrecm$INR, amiwrecm$ETA3, xlab='INR',ylab='ETACLM', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$INR, amiwrecm$ETA3), col=5, lwd=3) 
 
plot(amiwrecm$PT, amiwrecm$ETA4, xlab='PT',ylab='ETAQ', col=2, pch=16, cex=1.0) 
lines(lowess(amiwrecm$PT, amiwrecm$ETA4), col=5, lwd=3) 
plot(amiwrecm$PTT, amiwrecm$ETA4, xlab='PTT',ylab='ETAQ', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$PTT, amiwrecm$ETA4), col=5, lwd=3) 
plot(amiwrecm$INR, amiwrecm$ETA4, xlab='INR',ylab='ETAQ', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$INR, amiwrecm$ETA4), col=5, lwd=3) 
 
plot(amiwrecm$PT, amiwrecm$ETA5, xlab='PT',ylab='ETAV2', col=2, pch=16, cex=1.0) 
lines(lowess(amiwrecm$PT, amiwrecm$ETA5), col=5, lwd=3) 
plot(amiwrecm$PTT, amiwrecm$ETA5, xlab='PTT',ylab='ETAV2', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$PTT, amiwrecm$ETA5), col=5, lwd=3) 
plot(amiwrecm$INR, amiwrecm$ETA5, xlab='INR',ylab='ETAV2', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$INR, amiwrecm$ETA5), col=5, lwd=3) 
 
plot(amiwrecm$PT, amiwrecm$ETA6, xlab='PT',ylab='ETAV3', col=2, pch=16, cex=1.0) 
lines(lowess(amiwrecm$PT, amiwrecm$ETA6), col=5, lwd=3) 
plot(amiwrecm$PTT, amiwrecm$ETA6, xlab='PTT',ylab='ETAV3', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$PTT, amiwrecm$ETA6), col=5, lwd=3) 
plot(amiwrecm$INR, amiwrecm$ETA6, xlab='INR',ylab='ETAV3', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$INR, amiwrecm$ETA6), col=5, lwd=3) 
 





plot(amiwrecm$WT, amiwrecm$ETA1, xlab='Weight(kg)',ylab='ETACL1', col=2, 
pch=16, cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA1), col=5, lwd=3) 
plot(amiwrecm$BSA, amiwrecm$ETA1, xlab='BSA',ylab='ETACL1', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$BSA, amiwrecm$ETA1), col=5, lwd=3) 
 
 
plot(amiwrecm$WT, amiwrecm$ETA2, xlab='Weight(kg)',ylab='ETAV1', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA2), col=5, lwd=3) 
plot(amiwrecm$BSA, amiwrecm$ETA2, xlab='BSA',ylab='ETAV1', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$BSA, amiwrecm$ETA2), col=5, lwd=3) 
 
 
plot(amiwrecm$WT, amiwrecm$ETA3, xlab='Weight(kg)',ylab='ETACLM', col=2, 
pch=16, cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA3), col=5, lwd=3) 
plot(amiwrecm$BSA, amiwrecm$ETA3, xlab='BSA',ylab='ETACLM', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$BSA, amiwrecm$ETA3), col=5, lwd=3) 
 
 
plot(amiwrecm$WT, amiwrecm$ETA4, xlab='Weight(kg)',ylab='ETAQ', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA4), col=5, lwd=3) 
plot(amiwrecm$BSA, amiwrecm$ETA4, xlab='BSA',ylab='ETAQ', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$BSA, amiwrecm$ETA4), col=5, lwd=3) 
 
 
plot(amiwrecm$WT, amiwrecm$ETA5, xlab='Weight(kg)',ylab='ETAV2', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA5), col=5, lwd=3) 
plot(amiwrecm$BSA, amiwrecm$ETA5, xlab='BSA',ylab='ETAV2', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$BSA, amiwrecm$ETA5), col=5, lwd=3) 
 
plot(amiwrecm$WT, amiwrecm$ETA6, xlab='Weight(kg)',ylab='ETAV3', col=2, pch=16, 
cex=1.0) 
lines(lowess(amiwrecm$WT, amiwrecm$ETA6), col=5, lwd=3) 
plot(amiwrecm$BSA, amiwrecm$ETA6, xlab='BSA',ylab='ETAV3', col=2, pch=16, 
cex=1.0) 





# OBS VS PRED 
graphsheet() 
par(mar=c(5,5,4,4), cex=1.2) 
plot(amiwrecm$CONC, amiwrecm$IPRE, xlab='',ylab='', xlim=c(0,500),ylim=c(0,500), 
col=2, pch=16, cex=1.2) 
par(new=T, xaxs='d') 
plot(amiwrecm$CONC, amiwrecm$PRED, xlab='',ylab='', xlim=c(0,500),ylim=c(0,500), 
col=3, pch=17, cex=1.2) 
abline(0,1,lwd=3,col=5) 
title(main='Observed vs Predicted concentration - PK', xlab='Observed 
concentration(uM)', ylab='Predicted concentration(uM)', cex=1.2) 
















=2], lty=1, lwd=5, col=temp.col, type='l',cex=1.2) 
lines(amiwrecm$TIME[j&amiwrecm$CMT==2],amiwrecm$IPRE[j&amiwrecm$CMT=
=2], lty=4, lwd=5, col=temp.col, type='l',cex=1.2) 
title(paste('ID #',i,sep='')) 
key(text=list(c('DV','PRED','IPRED'), col=temp.col), lines=list(pch=temp.col, 
















=1], lty=1, lwd=5, col=temp.col, type='l',cex=1.2) 
lines(amiwrecm$TIME[j&amiwrecm$CMT==1],amiwrecm$IPRE[j&amiwrecm$CMT=
=1], lty=4, lwd=5, col=temp.col, type='l',cex=1.2) 
title(paste('ID #',i,sep='')) 
key(text=list(c('DV','PRED','IPRED'), col=temp.col), lines=list(pch=temp.col, 





tab=read.table('C:\\Documents and Settings\\zlu\\Desktop\\Human 






for (i in 1:n.rep){ 
 print(i) 
 temp.id=sample(unique(tab$CID), replace=T) 
 temp.data=NULL 
 while(length(temp.id)>0){ 
  temp.data=rbind(temp.data,tab[tab$CID%in%temp.id,]) 
  temp.id=temp.id[duplicated(temp.id)] 
 } 
 #temp.data=sort.col(temp.data,"@ALL", c('CID','TIME')) 
 exportData(temp.data,'C:\\Documents and Settings\\zlu\\Desktop\\Human 
study\\Lu\\myNonmemdatasetBoot.csv', delimiter=',', quote=F) 




 if (length(junk.pos)==0) next 
  #junk[junk.pos:(junk.pos+100)] 
  thetas=as.numeric(junk[(junk.pos[2]+20):(junk.pos[2]+27)]) 
 










plot(pk001m$WT, pk001m$ETA1, xlab='Weight(kg)',ylab='Estimated random effects on 
Clearance', col=2, pch=16, cex=1.0) 
lines(lowess(pk001m$WT, pk001m$ETA1), col=5, lwd=3) 
plot(pk001m$AGE, pk001m$ETA1, xlab='Age(yrs)',ylab='Estimated random effects on 
Clearance', col=2, pch=16, cex=1.0) 
lines(lowess(pk001m$AGE, pk001m$ETA1), col=5, lwd=3) 
boxplot(split(pk001m$ETA1,pk001m$SEX), names=c('Female','Male'), ylab='Estimated 
random effects on Clearance', cex=1.0) 
 
# WRES AND IWRES VS TIME 
graphsheet() 
par(mfrow=c(2,2),mar=c(5,5,4,4)) 
plot(wrlum$TIME, wrlum$IWRE, pch=16, col=2, xlab='TIME(mins)', ylab='IWRES', 
xlim=c(0,400), ylim=c(-2.5,2.5), cex=1.2) 
abline(h=0, lwd=3,col=5) 
lines(lowess(wrlum$TIME,wrlum$IWRE),lwd=3,col=3) 
plot(wrlum$TIME, abs(wrlum$IWRE), pch=16, col=2, xlab='TIME(mins)', 
ylab='|IWRES|', xlim=c(0,400), ylim=c(0,2.5), cex=1.2) 
lines(lowess(wrlum$TIME,abs(wrlum$IWRE)),lwd=3,col=3) 
 
# PARENT DRUG AND METABOLITE TOGETHER IN LOG SCALE 
graphsheet() 
par(mfrow=c(2,3),mar=c(5,5,4,4)) 




lines(aw2m$Time[j & aw2m$CMT==2], aw2m$DV[j & aw2m$CMT==2],pch=2, 
col=8,type='o',lty=1,lwd=3,cex=1.2) 
lines(aw2m$Time[j & aw2m$CMT==1], aw2m$DV[j & aw2m$CMT==1],pch=1, 
col=2,type='o',lty=1,lwd=3,cex=1.2) 
title(paste('ID #',i,sep='')) 






for (i in unique(aw2m$CID)){ 
j=aw2m$CID==i 
temp.col=temp.col+1 
lines(aw2m$Time[j & aw2m$CMT==2], aw2m$DV[j & aw2m$CMT==2],pch=temp.col, 
col=temp.col,type='o',lty=1,lwd=3,cex=1.2) 









# LOG SCALE OF CONCENTRATION VS TIME PROFILES OF WR1065 - 




for (i in unique(wrflm$ID)){ 
j=wrflm$ID==i 
temp.col=temp.col+1 





plot(wrflm$Time,wrflm$DV, type='n', xlim=c(0,400), ylim=c(0.01,100), log='y', 
xlab='Time(mins)', ylab='Blood concentration(uM)',cex=1.2) 
temp.col=0 






export.graph(FileName='C:\\Documents and Settings\\zheng lu\\Desktop\\Human 
study\\Lu\\wr.gif', Name='GSD2', ExportType='GIF') 
export.graph(FileName='C:\\Documents and Settings\\zheng lu\\Desktop\\Human 
study\\Lu\\wr.jpg', Name='GSD2', ExportType='JPG') 
 
# DV,PRED,IPRED ON ORIGINAL SCALE 
graphsheet() 
par(mar=c(5,5,4,4)) 
xyplot(CONC~TIME|ID, data=pk006, xlim=c(0,400), ylim=c(0,45), xlab='', ylab='', 
cex=1.2, pch=16, col=2) 
title(main='PK plots', xlab='Time(mins)',ylab='Concentration(uM)',cex=1.1) 
par(new=T, xaxs='d') 
xyplot(PRED~TIME|ID, data=pk006, xlim=c(0,400), ylim=c(0,45), xlab='', ylab='', 
cex=1.2, lwd=5,lty=1,type='l', col=3) 
par(new=T, xaxs='d') 
xyplot(IPRE~TIME|ID, data=pk006, xlim=c(0,400), ylim=c(0,45), xlab='', ylab='', 
cex=1.2, lwd=5,lty=4,type='l', col=5) 
export.graph(FileName='C:\\Documents and Settings\\zheng lu\\Desktop\\plot1.jpg', 
Name='GSD2', ExportType='JPG') 
